LIHUI personal page - To The Moon

LIHUI

LIHUI

No personal profile

57Follow

4Followers

0Topic

0Badge

2021-07-12

.

Oil Slips on Growing Threat of Delta Variant to Demand

2021-07-12

.

Oil Slips on Growing Threat of Delta Variant to Demand

2021-06-08

Like please

Controversial Biogen Alzheimer Drug Wins FDA Approval

2021-06-04

.

Sorry, the original content has been removed

2021-06-03

.

What You Should Know About Upstart Holdings' Valuation

2021-06-02

.

AMC Stock Is Surging Again. How to Make Sense of the Move.

2021-06-01

.

Sorry, the original content has been removed

2021-06-01

Weeee

Zoom Video to Report Q1 Earnings: What's in the Cards?

2021-05-28

.

Sorry, the original content has been removed

2021-05-27

.guu ya n

2021-05-27

.

GM restarting some plants hit by chips shortage

2021-05-26

.

Nasdaq seeks to remove restriction in direct listing plan

2021-05-20

.

Sorry, the original content has been removed

2021-05-18

.

4 Reasons to Buy Electronic Arts After Its Latest Earnings Report

2021-05-16

.

Why AMC Entertainment Stock Jumped Again Friday

2021-05-14

Thanks for sharing

Sorry, the original content has been removed

2021-05-12

$Starbucks(SBUX)$dhisndf

2021-05-12

Uppppzz

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3579418112520180,"uuid":"3579418112520180","gmtCreate":1616324571094,"gmtModify":1620830636840,"name":"LIHUI","pinyin":"lihui","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":57,"tweetSize":18,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.79%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":142067113,"gmtCreate":1626104891732,"gmtModify":1703753580042,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/142067113","repostId":"1143990601","repostType":4,"repost":{"id":"1143990601","pubTimestamp":1626102184,"share":"https://www.laohu8.com/m/news/1143990601?lang=&edition=full","pubTime":"2021-07-12 23:03","market":"fut","language":"en","title":"Oil Slips on Growing Threat of Delta Variant to Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=1143990601","media":"Bloomberg","summary":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurg","content":"<p>(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.</p>\n<p>Futures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.</p>\n<p>“As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.</p>\n<p>Fuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.</p>\n<p>China’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.</p>\n<p>“There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.</p>\n<p>The delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.</p>\n<p>Uncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.</p>\n<p>“They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.</p>\n<p>The International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil Slips on Growing Threat of Delta Variant to Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil Slips on Growing Threat of Delta Variant to Demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-12 23:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.\nFutures in New York fell as much as ...</p>\n\n<a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143990601","content_text":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.\nFutures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.\n“As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.\nFuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.\nChina’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.\n“There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.\nThe delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.\nUncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.\n“They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.\nThe International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":221,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":142064787,"gmtCreate":1626104877449,"gmtModify":1703753579716,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/142064787","repostId":"1143990601","repostType":4,"repost":{"id":"1143990601","pubTimestamp":1626102184,"share":"https://www.laohu8.com/m/news/1143990601?lang=&edition=full","pubTime":"2021-07-12 23:03","market":"fut","language":"en","title":"Oil Slips on Growing Threat of Delta Variant to Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=1143990601","media":"Bloomberg","summary":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurg","content":"<p>(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.</p>\n<p>Futures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.</p>\n<p>“As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.</p>\n<p>Fuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.</p>\n<p>China’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.</p>\n<p>“There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.</p>\n<p>The delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.</p>\n<p>Uncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.</p>\n<p>“They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.</p>\n<p>The International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil Slips on Growing Threat of Delta Variant to Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil Slips on Growing Threat of Delta Variant to Demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-12 23:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.\nFutures in New York fell as much as ...</p>\n\n<a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143990601","content_text":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.\nFutures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.\n“As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.\nFuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.\nChina’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.\n“There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.\nThe delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.\nUncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.\n“They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.\nThe International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":311,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114481303,"gmtCreate":1623087740802,"gmtModify":1704195859336,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/114481303","repostId":"1133110564","repostType":4,"repost":{"id":"1133110564","pubTimestamp":1623080895,"share":"https://www.laohu8.com/m/news/1133110564?lang=&edition=full","pubTime":"2021-06-07 23:48","market":"us","language":"en","title":"Controversial Biogen Alzheimer Drug Wins FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1133110564","media":"zerohedge","summary":"In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's ","content":"<p>In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's experimental drug for treating the physiological causes of Alzheimer's, as the first treatment to address an underlying cause of the disease despite the remaining controversy over the drug's decidedly mixed clinical trial results.</p>\n<p>AsReutersexplains, Aduhelm is one of a long list of drugs that have aimed to remove sticky deposits of a protein called amyloid beta from the brains of patients suffering from early-stage Alzheimer's in order to stave off the worst ravages of the disease, which is characterized by severe memory loss and the loss of the ability to care for oneself.</p>\n<p>The clinical trials for Aduhelm were the first to show that a reduction in these plaques (which are considered a hallmark symptom of the disease) can slow the clinical decline of a patient.</p>\n<p>The drug has created a rift in the professional community that was mentioned inthe FDA's press release: the agency said that the data included in the Biogen's submission - which were derived from two phase 3 clinical trials - were \"highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\" Many scientists opposed the drug's approval, saying it doesn't work.</p>\n<p>As a result, Biogen will be required to conduct another round of post-approval clinical studies (what the FDA is calling a \"Phase 4\" trial).</p>\n<p>Biogen's new drug is the first Alzheimer's treatment approved since 2003. Existing treatment courses for the disease don't do much to arrest the underlying causes, but rather are designed to make patients more comfortable.</p>\n<p>FDA approved Aduhelm to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, which allowed for the drug's approval thanks to the success it showed in reducing the amyloid beta brain plaque.</p>\n<p>Shares of Biogen climbed on the news, as did shares in other companies known to be working on alzheimer treatments, including Biogen rival Eli Lilly. The Nasdaq biotech index climbed to a session high.</p>\n<p><img src=\"https://static.tigerbbs.com/ac26030030981a2daa2396729b972e22\" tg-width=\"500\" tg-height=\"337\"><u><b>Read the full press release below:</b></u></p>\n<p><i>Today FDA approved&nbsp;Aduhelm (aducanumab)&nbsp;to treat patients with Alzheimer’s disease using the&nbsp;Accelerated Approval&nbsp;pathway, under which the FDA approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit.</i></p>\n<p><i>This approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer’s disease since 2003. Perhaps more significantly, Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer’s disease, the presence of amyloid beta plaques in the brain.&nbsp; The clinical trials for Aduhelm were the first to show that a reduction in these plaques—a hallmark finding in the brain of patients with Alzheimer’s—is expected to lead to a reduction in the clinical decline of this devastating form of dementia.</i></p>\n<p><i>We are well-aware of the attention surrounding this approval. We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review. Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.</i></p>\n<p><i>At the end of the day, we followed our usual course of action when making regulatory decisions in situations where the data are not straightforward. We examined the clinical trial findings with a fine-tooth comb, we solicited input from the&nbsp;Peripheral and Central Nervous System Drugs Advisory Committee, we listened to the perspectives of the patient community, and we reviewed all relevant data. We ultimately decided to use the Accelerated Approval pathway—a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit. In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy.</i></p>\n<p><i><b>What the Data Show</b></i></p>\n<p><i>The late-stage development program for Aduhelm consisted of two phase 3 clinical trials. One study met the primary endpoint, showing reduction in clinical decline. The second trial did not meet the primary endpoint. &nbsp;In all studies in which it was evaluated, however, Aduhelm consistently and very convincingly reduced the level of amyloid plaques in the brain in a dose- and time-dependent fashion. &nbsp;It is expected that the reduction in amyloid plaque will result in a reduction in clinical decline.</i></p>\n<p><i>We know that the Peripheral and Central Nervous System Drugs Advisory Committee, which convened in November 2020 to review the clinical trial data and discuss the evidence supporting the Aduhelm application, did not agree that it was reasonable to consider the clinical benefit of the one successful trial as the primary evidence supporting approval. The option of Accelerated Approval was not discussed by the Advisory Committee. As mentioned above, treatment with Aduhelm was clearly shown in all trials to substantially reduce amyloid beta plaques. This reduction in plaques is reasonably likely to result in clinical benefit. After the Advisory Committee provided its feedback, our review and deliberations continued, and we decided that the evidence presented in the Aduhelm application met the standard for Accelerated Approval. We thank the Advisory Committee for its independent review of the data and valuable advice.</i></p>\n<p><i><b>Accelerated Approval</b></i></p>\n<p><i>The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need.&nbsp; Approval is based on a surrogate or intermediate clinical endpoint (in this case reduction of amyloid plaque in the brain).&nbsp; A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.</i></p>\n<p><i>Drug companies are required to conduct post-approval studies to verify the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial does not verify the drug’s anticipated clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.</i></p>\n<p><i><b>The Devastation of Alzheimer’s Disease</b></i></p>\n<p><i>With all this said, we are extremely aware of the gradual and cumulative devastation that Alzheimer’s disease causes, as patients lose their memory and cognitive functioning over time. In late-stage disease, people can no longer hold a conversation or respond to their environment. On average, a person with Alzheimer’s disease lives four to eight years after diagnosis, but some patients can live up to 20 years with the disease.</i></p>\n<p><i>The need for treatments is urgent: right now, more than 6 million Americans are living with Alzheimer’s disease and this number is expected to grow as the population ages. Alzheimer's is the sixth leading cause of death in the United States.</i></p>\n<p><i>Although the Aduhelm data are complicated with respect to its clinical benefits, FDA has determined that there is substantial evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients. &nbsp;As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease.</i></p>\n<p><i>FDA will continue to monitor Aduhelm as it reaches the market and ultimately the patient’s bedside. Additionally, FDA is requiring Biogen to conduct a post-approval clinical trial to verify the drug’s clinical benefit. If the drug does not work as intended, we can take steps to remove it from the market. But hopefully, we will see further evidence of benefit in the clinical trial and as greater numbers of people receive Aduhelm. As an agency, we will also continue to work to foster drug development for this catastrophic disease.</i></p>","source":"lsy1583725640930","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Controversial Biogen Alzheimer Drug Wins FDA Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nControversial Biogen Alzheimer Drug Wins FDA Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 23:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/breakthrough-biogen-alzheimer-drug-wins-fda-approval?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's experimental drug for treating the physiological causes of Alzheimer's, as the first treatment to ...</p>\n\n<a href=\"https://www.zerohedge.com/markets/breakthrough-biogen-alzheimer-drug-wins-fda-approval?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.zerohedge.com/markets/breakthrough-biogen-alzheimer-drug-wins-fda-approval?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133110564","content_text":"In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's experimental drug for treating the physiological causes of Alzheimer's, as the first treatment to address an underlying cause of the disease despite the remaining controversy over the drug's decidedly mixed clinical trial results.\nAsReutersexplains, Aduhelm is one of a long list of drugs that have aimed to remove sticky deposits of a protein called amyloid beta from the brains of patients suffering from early-stage Alzheimer's in order to stave off the worst ravages of the disease, which is characterized by severe memory loss and the loss of the ability to care for oneself.\nThe clinical trials for Aduhelm were the first to show that a reduction in these plaques (which are considered a hallmark symptom of the disease) can slow the clinical decline of a patient.\nThe drug has created a rift in the professional community that was mentioned inthe FDA's press release: the agency said that the data included in the Biogen's submission - which were derived from two phase 3 clinical trials - were \"highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\" Many scientists opposed the drug's approval, saying it doesn't work.\nAs a result, Biogen will be required to conduct another round of post-approval clinical studies (what the FDA is calling a \"Phase 4\" trial).\nBiogen's new drug is the first Alzheimer's treatment approved since 2003. Existing treatment courses for the disease don't do much to arrest the underlying causes, but rather are designed to make patients more comfortable.\nFDA approved Aduhelm to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, which allowed for the drug's approval thanks to the success it showed in reducing the amyloid beta brain plaque.\nShares of Biogen climbed on the news, as did shares in other companies known to be working on alzheimer treatments, including Biogen rival Eli Lilly. The Nasdaq biotech index climbed to a session high.\nRead the full press release below:\nToday FDA approved Aduhelm (aducanumab) to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, under which the FDA approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit.\nThis approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer’s disease since 2003. Perhaps more significantly, Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer’s disease, the presence of amyloid beta plaques in the brain.  The clinical trials for Aduhelm were the first to show that a reduction in these plaques—a hallmark finding in the brain of patients with Alzheimer’s—is expected to lead to a reduction in the clinical decline of this devastating form of dementia.\nWe are well-aware of the attention surrounding this approval. We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review. Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\nAt the end of the day, we followed our usual course of action when making regulatory decisions in situations where the data are not straightforward. We examined the clinical trial findings with a fine-tooth comb, we solicited input from the Peripheral and Central Nervous System Drugs Advisory Committee, we listened to the perspectives of the patient community, and we reviewed all relevant data. We ultimately decided to use the Accelerated Approval pathway—a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit. In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy.\nWhat the Data Show\nThe late-stage development program for Aduhelm consisted of two phase 3 clinical trials. One study met the primary endpoint, showing reduction in clinical decline. The second trial did not meet the primary endpoint.  In all studies in which it was evaluated, however, Aduhelm consistently and very convincingly reduced the level of amyloid plaques in the brain in a dose- and time-dependent fashion.  It is expected that the reduction in amyloid plaque will result in a reduction in clinical decline.\nWe know that the Peripheral and Central Nervous System Drugs Advisory Committee, which convened in November 2020 to review the clinical trial data and discuss the evidence supporting the Aduhelm application, did not agree that it was reasonable to consider the clinical benefit of the one successful trial as the primary evidence supporting approval. The option of Accelerated Approval was not discussed by the Advisory Committee. As mentioned above, treatment with Aduhelm was clearly shown in all trials to substantially reduce amyloid beta plaques. This reduction in plaques is reasonably likely to result in clinical benefit. After the Advisory Committee provided its feedback, our review and deliberations continued, and we decided that the evidence presented in the Aduhelm application met the standard for Accelerated Approval. We thank the Advisory Committee for its independent review of the data and valuable advice.\nAccelerated Approval\nThe FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need.  Approval is based on a surrogate or intermediate clinical endpoint (in this case reduction of amyloid plaque in the brain).  A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.\nDrug companies are required to conduct post-approval studies to verify the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial does not verify the drug’s anticipated clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.\nThe Devastation of Alzheimer’s Disease\nWith all this said, we are extremely aware of the gradual and cumulative devastation that Alzheimer’s disease causes, as patients lose their memory and cognitive functioning over time. In late-stage disease, people can no longer hold a conversation or respond to their environment. On average, a person with Alzheimer’s disease lives four to eight years after diagnosis, but some patients can live up to 20 years with the disease.\nThe need for treatments is urgent: right now, more than 6 million Americans are living with Alzheimer’s disease and this number is expected to grow as the population ages. Alzheimer's is the sixth leading cause of death in the United States.\nAlthough the Aduhelm data are complicated with respect to its clinical benefits, FDA has determined that there is substantial evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients.  As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease.\nFDA will continue to monitor Aduhelm as it reaches the market and ultimately the patient’s bedside. Additionally, FDA is requiring Biogen to conduct a post-approval clinical trial to verify the drug’s clinical benefit. If the drug does not work as intended, we can take steps to remove it from the market. But hopefully, we will see further evidence of benefit in the clinical trial and as greater numbers of people receive Aduhelm. As an agency, we will also continue to work to foster drug development for this catastrophic disease.","news_type":1},"isVote":1,"tweetType":1,"viewCount":444,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":118594655,"gmtCreate":1622736920377,"gmtModify":1704190239905,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/118594655","repostId":"2140247164","repostType":4,"isVote":1,"tweetType":1,"viewCount":229,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":111320436,"gmtCreate":1622653635125,"gmtModify":1704188281962,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/111320436","repostId":"2140448417","repostType":4,"repost":{"id":"2140448417","pubTimestamp":1622648316,"share":"https://www.laohu8.com/m/news/2140448417?lang=&edition=full","pubTime":"2021-06-02 23:38","market":"us","language":"en","title":"What You Should Know About Upstart Holdings' Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2140448417","media":"Motley Fool","summary":"Investors are paying a big premium for this artificial intelligence-driven lending disruptor.","content":"<p>When it comes to lending money, the fundamentals haven't changed much over the years. Banks typically want to see a steady income, responsible spending habits, and an item of security -- like a house or a car -- before writing loans. Technology has improved the process significantly, and it continues to evolve to provide more information to lenders and more options for consumers.</p>\n<p><b>Upstart Holdings </b>(NASDAQ:UPST) is all-digital lending platform with an artificial intelligence model that measures alternative metrics when assessing a potential borrower. The company uses the technology to help originate loans for lenders, and its business model is already delivering profits. Its valuation, though, has ballooned as enthusiastic investors bet heavily on the stock -- and it could take <i>years </i>for profits to catch up. Is it still worth an investment today?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/47a7615523095573d390a24d22976d99\" tg-width=\"700\" tg-height=\"466\"><span>Image Source: Getty Images.</span></p>\n<h2>How it works</h2>\n<p>Upstart partners with banks that write unsecured loans, to borrowers who might have a moderate to low income and might be used to paying higher interest rates. Some of its offerings include personal loans, wedding loans, credit card consolidation, and car loans. The annual percentage rate (interest) for an Upstart loan is in the 8.27% to 35.99% range, depending on the product.</p>\n<p>Total non-housing consumer debt in the U.S. stood at more than $4.1 trillion in Q1, including about $745 billion in ''revolving credit'' (credit cards and other loans consumers can pay down, reuse, and carry balances on). Upstart has a substantial market opportunity that it has only just begun to tap.</p>\n<p>Potential borrowers can submit a loan application through a bank that uses Upstart's application programming interface (API). Behind the scenes, the company's artificial intelligence is assessing the proposed loan, looking at more than 1,000 data points to provide a decision instantly (in most cases).</p>\n<p>Upstart's algorithm has the ability to assess a borrower based on nontraditional metrics. For example, it accounts for a borrower's education and where they went to school, in addition to their job history, rather than just on income and assets. The company claims its decision process can reduce default rates by 75%. In fact, it boasts 173% <i>more</i> approvals for the same overall loan loss rate.</p>\n<h2>Priced for perfection</h2>\n<p>Banks are usually valued methodically, using metrics like tangible book value and earnings per share. Investors have decades' worth of historical earnings and valuations to work with when assessing financial institutions. New technology makes the process a bit different -- investors don't have the same history to study, and disruptive companies can therefore be difficult to value.</p>\n<p>At the moment, Upstart is trading like a growth-oriented tech company, and this <i>could </i>be warranted since it's effectively a software business.</p>\n<table>\n <thead>\n  <tr>\n   <th><p>Year</p></th>\n   <th><p>Revenue</p></th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td><p>2018</p></td>\n   <td><p>$99 million</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$164 million</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$233 million</p></td>\n  </tr>\n  <tr>\n   <td><p>Q1 2021</p></td>\n   <td><p>$121 million</p></td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: Company filings.</p>\n<p>At Wednesday's prices, Upstart has a market cap over $11 billion, with full-year 2020 net income of $6 million. The company beat that total in this year's first quarter, with a net income of $10.1 million, so you can see how fast it's growing. However, it will likely need to earn significantly more for its current valuation to remain at these lofty levels.</p>\n<p>The company expects to earn $500 million in revenue in 2021 -- which would represent 114% in yearly revenue growth -- and based on the Q1 result, this could translate to over $40 million in net income.</p>\n<p>For the company to keep up this pace, it will most likely need new catalysts, and it likely has them.&nbsp;Upstart is now offering its platform technology to auto financiers, to capture a piece of the single largest lending segment after housing. Total auto loans in the U.S. grew to $1.37 trillion in 2020, and car shortages have led to higher prices and pent up demand across the board.</p>\n<p>The company has trailing 12-month revenue of $290 million, so the stock currently trades at a revenue multiple of roughly 38 times. That's higher than <b>Tesla</b>'s! With the growth opportunities Upstart is expecting, the company has the opportunity to grow its way into a less intimidating multiple over the next few years.&nbsp;But if you're buying it today, Upstart <i>must</i> deliver.</p>\n<h2>Looking forward</h2>\n<p>Upstart is showing promising growth in originations, with $1.73 billion in Q1, up 102% year over year on 169,750 total loans. This is <a href=\"https://laohu8.com/S/AONE\">one</a> of the best metrics to measure the company's performance, as it translates directly to revenue. Since the company's algorithm instantly and automatically approved 71% of those loans, the scalability of this business is potentially enormous.</p>\n<p>If the company continues to deliver growth in net income, its stock will likely remain buoyant -- although the risk to the valuation <i>might </i>be to the downside, depending how fast that growth is. The question for investors is whether there is enough upside potential from here to warrant that risk. Upstart is guiding for a similar amount of net income in the second quarter as it delivered in Q1, putting the company on track to generate less than $50 million this year. That might not be enough to sustain its current market cap.</p>\n<p>However, for investors with a five-year time horizon (or more), Upstart could present a strong growth opportunity.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What You Should Know About Upstart Holdings' Valuation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat You Should Know About Upstart Holdings' Valuation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-02 23:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/02/what-you-should-know-about-upstart-holdings-valuat/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When it comes to lending money, the fundamentals haven't changed much over the years. Banks typically want to see a steady income, responsible spending habits, and an item of security -- like a house ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/02/what-you-should-know-about-upstart-holdings-valuat/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UPST":"Upstart Holdings, Inc."},"source_url":"https://www.fool.com/investing/2021/06/02/what-you-should-know-about-upstart-holdings-valuat/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140448417","content_text":"When it comes to lending money, the fundamentals haven't changed much over the years. Banks typically want to see a steady income, responsible spending habits, and an item of security -- like a house or a car -- before writing loans. Technology has improved the process significantly, and it continues to evolve to provide more information to lenders and more options for consumers.\nUpstart Holdings (NASDAQ:UPST) is all-digital lending platform with an artificial intelligence model that measures alternative metrics when assessing a potential borrower. The company uses the technology to help originate loans for lenders, and its business model is already delivering profits. Its valuation, though, has ballooned as enthusiastic investors bet heavily on the stock -- and it could take years for profits to catch up. Is it still worth an investment today?\nImage Source: Getty Images.\nHow it works\nUpstart partners with banks that write unsecured loans, to borrowers who might have a moderate to low income and might be used to paying higher interest rates. Some of its offerings include personal loans, wedding loans, credit card consolidation, and car loans. The annual percentage rate (interest) for an Upstart loan is in the 8.27% to 35.99% range, depending on the product.\nTotal non-housing consumer debt in the U.S. stood at more than $4.1 trillion in Q1, including about $745 billion in ''revolving credit'' (credit cards and other loans consumers can pay down, reuse, and carry balances on). Upstart has a substantial market opportunity that it has only just begun to tap.\nPotential borrowers can submit a loan application through a bank that uses Upstart's application programming interface (API). Behind the scenes, the company's artificial intelligence is assessing the proposed loan, looking at more than 1,000 data points to provide a decision instantly (in most cases).\nUpstart's algorithm has the ability to assess a borrower based on nontraditional metrics. For example, it accounts for a borrower's education and where they went to school, in addition to their job history, rather than just on income and assets. The company claims its decision process can reduce default rates by 75%. In fact, it boasts 173% more approvals for the same overall loan loss rate.\nPriced for perfection\nBanks are usually valued methodically, using metrics like tangible book value and earnings per share. Investors have decades' worth of historical earnings and valuations to work with when assessing financial institutions. New technology makes the process a bit different -- investors don't have the same history to study, and disruptive companies can therefore be difficult to value.\nAt the moment, Upstart is trading like a growth-oriented tech company, and this could be warranted since it's effectively a software business.\n\n\n\nYear\nRevenue\n\n\n\n\n2018\n$99 million\n\n\n2019\n$164 million\n\n\n2020\n$233 million\n\n\nQ1 2021\n$121 million\n\n\n\nData source: Company filings.\nAt Wednesday's prices, Upstart has a market cap over $11 billion, with full-year 2020 net income of $6 million. The company beat that total in this year's first quarter, with a net income of $10.1 million, so you can see how fast it's growing. However, it will likely need to earn significantly more for its current valuation to remain at these lofty levels.\nThe company expects to earn $500 million in revenue in 2021 -- which would represent 114% in yearly revenue growth -- and based on the Q1 result, this could translate to over $40 million in net income.\nFor the company to keep up this pace, it will most likely need new catalysts, and it likely has them. Upstart is now offering its platform technology to auto financiers, to capture a piece of the single largest lending segment after housing. Total auto loans in the U.S. grew to $1.37 trillion in 2020, and car shortages have led to higher prices and pent up demand across the board.\nThe company has trailing 12-month revenue of $290 million, so the stock currently trades at a revenue multiple of roughly 38 times. That's higher than Tesla's! With the growth opportunities Upstart is expecting, the company has the opportunity to grow its way into a less intimidating multiple over the next few years. But if you're buying it today, Upstart must deliver.\nLooking forward\nUpstart is showing promising growth in originations, with $1.73 billion in Q1, up 102% year over year on 169,750 total loans. This is one of the best metrics to measure the company's performance, as it translates directly to revenue. Since the company's algorithm instantly and automatically approved 71% of those loans, the scalability of this business is potentially enormous.\nIf the company continues to deliver growth in net income, its stock will likely remain buoyant -- although the risk to the valuation might be to the downside, depending how fast that growth is. The question for investors is whether there is enough upside potential from here to warrant that risk. Upstart is guiding for a similar amount of net income in the second quarter as it delivered in Q1, putting the company on track to generate less than $50 million this year. That might not be enough to sustain its current market cap.\nHowever, for investors with a five-year time horizon (or more), Upstart could present a strong growth opportunity.","news_type":1},"isVote":1,"tweetType":1,"viewCount":262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":111963117,"gmtCreate":1622649396339,"gmtModify":1704188139993,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".&nbsp;","listText":".&nbsp;","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/111963117","repostId":"1188552613","repostType":4,"repost":{"id":"1188552613","pubTimestamp":1622627641,"share":"https://www.laohu8.com/m/news/1188552613?lang=&edition=full","pubTime":"2021-06-02 17:54","market":"us","language":"en","title":"AMC Stock Is Surging Again. How to Make Sense of the Move.","url":"https://stock-news.laohu8.com/highlight/detail?id=1188552613","media":"Barrons","summary":"AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, th","content":"<p>AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, that social media-fueled investor frenzy that has launched the likes of&nbsp;GameStop&nbsp;and&nbsp;BlackBerry&nbsp;into speculative territory.</p>\n<p>But it’s possible that traditional investors have missed a fundamental change in the movie theater business—and it wouldn’t be the first time.</p>\n<p>Shares of AMC (ticker: AMC) surged 23% on Tuesday, closing at $32.04—just off an all-time high of $36.72 set in late May. That puts the movie-theater chain’s market capitalization at roughly $16 billion, more than 15 times what it was in 2018, a record-breaking year at the box office.&nbsp;Shares were up another 34%, to $42.92, in premarket trading Wednesday.</p>\n<p>Even if investors missed an inflection point, though, the math doesn’t add up. The reason might be that market cap isn’t the right measure. Maybe it’s enterprise value, which is essentially market cap and debt. AMC’s enterprise value is about $26 billion, compared with $6.2 billion or so at the end of 2018.</p>\n<p>AMC added debt during the pandemic as theaters in the country’s biggest cities were dark for months. And the numbers make it easy to understand why: The U.S. box office in 2020 generated about $2.1 billion in ticket sales, down 81% from the 2018 record of $11.9 billion.</p>\n<p>So, it seems investors have been vexed by movie theater economics. But it wouldn’t be the first time. The industry essentially went belly up at the turn of the millennium. Regal Cinemas, for instance, declared bankruptcy in 2001.</p>\n<p>Back then, the industry had plenty of capacity because of a new theater design—stadium seating that gave a better view of the screen. That shift meant movie theater chains had to renovate or risk losing all their patrons to movie theaters that offered the better view. In the end, too many seats and not enough patrons meant the return on the stadium-seating investments never materialized.</p>\n<p>The upshot was consolidation. With fewer operators, the number of screens stabilized. Between 2002 and 2007, Regal Cinemas became a cash-generating machine because the stock was mispriced. The stock returned 21% a year on average. The S&amp;P 500 and Dow Jones Industrial Average both returned less than 9% a year on average over the same period.</p>\n<p>In those days, Regal Cinema’s enterprise value about $5 billion, or about 50% of total U.S. box office sales. That’s far short of AMC today. Something new has to be different for AMC to be worth it.</p>\n<p>Maybe the movie theater business is going to go through another period of consolidation, which can usher in another golden age of returns. AMC’s Tuesday gains, in fact, were catalyzed by new capital raised so the company could go on the offensive, acquiring defunct chains. Monopolies, after all, can be good for stock returns.</p>\n<p>If AMC can increase market share and the U.S. box office sales can return to 2018 levels in a few years, total sales at might be $9 billion—$6 billion from tickets and $3 billion from concessions. Sales in 2018 amounted to $5.5 billion.</p>\n<p>Then, with better gross profit margins derived from larger scale, AMC might be able to generate $600 million in free cash flow annually, which puts the stock at about a 4% free cash flow yield. The S&amp;P 500 trades for about a 3% free cash flow yield. The numbers can work—if they’re stretched.</p>\n<p>There are problems with this scenario, though. There are lots of ifs and mights—and AMC has never generated cash flow like that in the past. Arriving at $600 million in free cash flow is more about justifying current valuations than predicting what is likely.</p>\n<p>Also, with mergers and acquisitions, AMC market shares might rise, but there are still competitors. Regal Cinemas is still out there, owned by Cineworld Holdings (CINE. London). So is Cinemark (CNK). There’s not a true monopoly.</p>\n<p>AMC and its peers have to deal with streaming, too. Windows for exclusive theater showings are shrinking. The pandemic has accelerated that. And if AMC gets too large and demanding for movie makers, the talent can always go to streaming faster, hurting box office sales.</p>\n<p>There is also the problem of the peer stocks. They aren’t trading like this is a brave new world for theaters. Cineworld stock is up 484% from its 52-week low, but shares are still off 72% from all-time highs. Cinemark shares are up 222% from their 52-week low. They are down 47% from their all-time high.</p>\n<p>AMC stock, again, is up almost 1,600% from its 52-week low and is down just 13% from its May all-time high.</p>\n<p>Wall Street just doesn’t see the potential either. Nine analysts cover the stock. The average analyst price target is about $5. Before the pandemic, the average analyst price target was $15. But there were fewer shares back then. The old target enterprise value was roughly $7 billion. It’s tough to get from $7 billion to $26 billion predicting better margins.</p>\n<p>Analysts do have positive free cash flow modeled, though–$13 million in 2022 and $90 million in 2023. That’s a long way from $600 million.</p>\n<p>And that’s just another way of saying that AMC bulls are a long way from making the math work.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC Stock Is Surging Again. How to Make Sense of the Move.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC Stock Is Surging Again. How to Make Sense of the Move.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-02 17:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/amc-rockets-higher-is-it-worth-it-maybe-51622594691?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, that social media-fueled investor frenzy that has launched the likes of GameStop and BlackBerry into ...</p>\n\n<a href=\"https://www.barrons.com/articles/amc-rockets-higher-is-it-worth-it-maybe-51622594691?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.barrons.com/articles/amc-rockets-higher-is-it-worth-it-maybe-51622594691?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188552613","content_text":"AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, that social media-fueled investor frenzy that has launched the likes of GameStop and BlackBerry into speculative territory.\nBut it’s possible that traditional investors have missed a fundamental change in the movie theater business—and it wouldn’t be the first time.\nShares of AMC (ticker: AMC) surged 23% on Tuesday, closing at $32.04—just off an all-time high of $36.72 set in late May. That puts the movie-theater chain’s market capitalization at roughly $16 billion, more than 15 times what it was in 2018, a record-breaking year at the box office. Shares were up another 34%, to $42.92, in premarket trading Wednesday.\nEven if investors missed an inflection point, though, the math doesn’t add up. The reason might be that market cap isn’t the right measure. Maybe it’s enterprise value, which is essentially market cap and debt. AMC’s enterprise value is about $26 billion, compared with $6.2 billion or so at the end of 2018.\nAMC added debt during the pandemic as theaters in the country’s biggest cities were dark for months. And the numbers make it easy to understand why: The U.S. box office in 2020 generated about $2.1 billion in ticket sales, down 81% from the 2018 record of $11.9 billion.\nSo, it seems investors have been vexed by movie theater economics. But it wouldn’t be the first time. The industry essentially went belly up at the turn of the millennium. Regal Cinemas, for instance, declared bankruptcy in 2001.\nBack then, the industry had plenty of capacity because of a new theater design—stadium seating that gave a better view of the screen. That shift meant movie theater chains had to renovate or risk losing all their patrons to movie theaters that offered the better view. In the end, too many seats and not enough patrons meant the return on the stadium-seating investments never materialized.\nThe upshot was consolidation. With fewer operators, the number of screens stabilized. Between 2002 and 2007, Regal Cinemas became a cash-generating machine because the stock was mispriced. The stock returned 21% a year on average. The S&P 500 and Dow Jones Industrial Average both returned less than 9% a year on average over the same period.\nIn those days, Regal Cinema’s enterprise value about $5 billion, or about 50% of total U.S. box office sales. That’s far short of AMC today. Something new has to be different for AMC to be worth it.\nMaybe the movie theater business is going to go through another period of consolidation, which can usher in another golden age of returns. AMC’s Tuesday gains, in fact, were catalyzed by new capital raised so the company could go on the offensive, acquiring defunct chains. Monopolies, after all, can be good for stock returns.\nIf AMC can increase market share and the U.S. box office sales can return to 2018 levels in a few years, total sales at might be $9 billion—$6 billion from tickets and $3 billion from concessions. Sales in 2018 amounted to $5.5 billion.\nThen, with better gross profit margins derived from larger scale, AMC might be able to generate $600 million in free cash flow annually, which puts the stock at about a 4% free cash flow yield. The S&P 500 trades for about a 3% free cash flow yield. The numbers can work—if they’re stretched.\nThere are problems with this scenario, though. There are lots of ifs and mights—and AMC has never generated cash flow like that in the past. Arriving at $600 million in free cash flow is more about justifying current valuations than predicting what is likely.\nAlso, with mergers and acquisitions, AMC market shares might rise, but there are still competitors. Regal Cinemas is still out there, owned by Cineworld Holdings (CINE. London). So is Cinemark (CNK). There’s not a true monopoly.\nAMC and its peers have to deal with streaming, too. Windows for exclusive theater showings are shrinking. The pandemic has accelerated that. And if AMC gets too large and demanding for movie makers, the talent can always go to streaming faster, hurting box office sales.\nThere is also the problem of the peer stocks. They aren’t trading like this is a brave new world for theaters. Cineworld stock is up 484% from its 52-week low, but shares are still off 72% from all-time highs. Cinemark shares are up 222% from their 52-week low. They are down 47% from their all-time high.\nAMC stock, again, is up almost 1,600% from its 52-week low and is down just 13% from its May all-time high.\nWall Street just doesn’t see the potential either. Nine analysts cover the stock. The average analyst price target is about $5. Before the pandemic, the average analyst price target was $15. But there were fewer shares back then. The old target enterprise value was roughly $7 billion. It’s tough to get from $7 billion to $26 billion predicting better margins.\nAnalysts do have positive free cash flow modeled, though–$13 million in 2022 and $90 million in 2023. That’s a long way from $600 million.\nAnd that’s just another way of saying that AMC bulls are a long way from making the math work.","news_type":1},"isVote":1,"tweetType":1,"viewCount":407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119454643,"gmtCreate":1622560637282,"gmtModify":1704186405956,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/119454643","repostId":"2140617694","repostType":4,"isVote":1,"tweetType":1,"viewCount":583,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119455704,"gmtCreate":1622560602508,"gmtModify":1704186405138,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Weeee","listText":"Weeee","text":"Weeee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/119455704","repostId":"2138889344","repostType":4,"repost":{"id":"2138889344","pubTimestamp":1622546894,"share":"https://www.laohu8.com/m/news/2138889344?lang=&edition=full","pubTime":"2021-06-01 19:28","market":"us","language":"en","title":"Zoom Video to Report Q1 Earnings: What's in the Cards?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138889344","media":"Zacks","summary":"Zoom Video Communications is set to report first-quarter fiscal 2022 results on Jun 1.For the quarte","content":"<p><b><a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications</b> is set to report first-quarter fiscal 2022 results on Jun 1.</p><p>For the quarter, the company expects non-GAAP earnings between 95 cents and 97 cents per share. Total revenues are expected between $900 million and $905 million.</p><p>The Zacks Consensus Estimate for earnings stayed at 97 cents per share over the past 30 days. The company had reported earnings of 20 cents per share in the year-ago quarter.</p><p>The consensus mark for revenues is pegged at $905.2 million, suggesting 175.8% growth from the figure reported in the year-ago quarter.</p><h3>Zoom Video Communications, Inc. Price and EPS Surprise</h3><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dc75f53073be8992ce4f8cf58d4ebd0a\" tg-width=\"539\" tg-height=\"264\"><span>Zoom Video Communications, Inc. price-eps-surprise | Zoom Video Communications, Inc. Quote</span></p><p>Zoom’s earnings beat the Zacks Consensus Estimate in all of the past four quarters, the average surprise being 73.2%.</p><p>Let’s see how things have shaped up for this announcement.</p><h3>Factors to Watch</h3><p>Zoom’s fiscal first-quarter revenues are expected to have benefited from the coronavirus-induced work-from-home and online-learning wave despite the vaccination campaigns.</p><p>Notably, the company’s freemium business model helps it win customers rapidly, whom it can later convert into paying customers. Net dollar-expansion rate on a trailing twelve-month basis was more than 156% in fourth-quarter fiscal 2021. The momentum is expected to have continued in the to-be-reported quarter.</p><p>Further, the availability of Zoom For Home, which supports remote working for business professionals, has been a key catalyst.</p><p>Additionally, this Zacks Rank #2 (Buy) company’s strong partner base, that includes the likes of <b>Atlassian</b>, <b><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a></b> and Dropbox, is expected to have benefited the company in winning enterprise customers in fiscal first quarter. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.</p><p>However, Zoom Video continues to face significant competition from the likes of <b>Cisco</b>, Microsoft and Google Meet. This might have led to loss in small and medium business customers, which is likely to have hurt top-line growth.</p><h3>Key Q1 Highlights</h3><p>During the to-be-reported quarter, Zoom announced $100 million venture fund called Zoom Apps Fund, aimed at stimulating growth of Zoom’s ecosystem of Zoom Apps, integrations, developer platform and hardware.</p><p>Moreover, during the quarter, Zoom and Formula 1 announced that they have entered a new extensive multi-year partnership across the upcoming 2021 FIA Formula One World Championship racing season and beyond.</p><p>Further, in February, Zoom announced the availability of Zoom Rooms that will help organizations safely re-enter the office and sustain an “everywhere workforce”.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zoom Video to Report Q1 Earnings: What's in the Cards?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZoom Video to Report Q1 Earnings: What's in the Cards?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 19:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zacks.com/stock/news/1619568/zoom-video-zm-to-report-q1-earnings-whats-in-the-cards?art_rec=quote-stock_overview-zacks_news-ID05-txt-1619568><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zoom Video Communications is set to report first-quarter fiscal 2022 results on Jun 1.For the quarter, the company expects non-GAAP earnings between 95 cents and 97 cents per share. Total revenues are...</p>\n\n<a href=\"https://www.zacks.com/stock/news/1619568/zoom-video-zm-to-report-q1-earnings-whats-in-the-cards?art_rec=quote-stock_overview-zacks_news-ID05-txt-1619568\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZM":"Zoom"},"source_url":"https://www.zacks.com/stock/news/1619568/zoom-video-zm-to-report-q1-earnings-whats-in-the-cards?art_rec=quote-stock_overview-zacks_news-ID05-txt-1619568","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138889344","content_text":"Zoom Video Communications is set to report first-quarter fiscal 2022 results on Jun 1.For the quarter, the company expects non-GAAP earnings between 95 cents and 97 cents per share. Total revenues are expected between $900 million and $905 million.The Zacks Consensus Estimate for earnings stayed at 97 cents per share over the past 30 days. The company had reported earnings of 20 cents per share in the year-ago quarter.The consensus mark for revenues is pegged at $905.2 million, suggesting 175.8% growth from the figure reported in the year-ago quarter.Zoom Video Communications, Inc. Price and EPS SurpriseZoom Video Communications, Inc. price-eps-surprise | Zoom Video Communications, Inc. QuoteZoom’s earnings beat the Zacks Consensus Estimate in all of the past four quarters, the average surprise being 73.2%.Let’s see how things have shaped up for this announcement.Factors to WatchZoom’s fiscal first-quarter revenues are expected to have benefited from the coronavirus-induced work-from-home and online-learning wave despite the vaccination campaigns.Notably, the company’s freemium business model helps it win customers rapidly, whom it can later convert into paying customers. Net dollar-expansion rate on a trailing twelve-month basis was more than 156% in fourth-quarter fiscal 2021. The momentum is expected to have continued in the to-be-reported quarter.Further, the availability of Zoom For Home, which supports remote working for business professionals, has been a key catalyst.Additionally, this Zacks Rank #2 (Buy) company’s strong partner base, that includes the likes of Atlassian, ServiceNow and Dropbox, is expected to have benefited the company in winning enterprise customers in fiscal first quarter. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.However, Zoom Video continues to face significant competition from the likes of Cisco, Microsoft and Google Meet. This might have led to loss in small and medium business customers, which is likely to have hurt top-line growth.Key Q1 HighlightsDuring the to-be-reported quarter, Zoom announced $100 million venture fund called Zoom Apps Fund, aimed at stimulating growth of Zoom’s ecosystem of Zoom Apps, integrations, developer platform and hardware.Moreover, during the quarter, Zoom and Formula 1 announced that they have entered a new extensive multi-year partnership across the upcoming 2021 FIA Formula One World Championship racing season and beyond.Further, in February, Zoom announced the availability of Zoom Rooms that will help organizations safely re-enter the office and sustain an “everywhere workforce”.","news_type":1},"isVote":1,"tweetType":1,"viewCount":417,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":134326282,"gmtCreate":1622209102946,"gmtModify":1704181507874,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/134326282","repostId":"2138107027","repostType":4,"isVote":1,"tweetType":1,"viewCount":246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":135084783,"gmtCreate":1622122701142,"gmtModify":1704179864159,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".guu ya n","listText":".guu ya n","text":".guu ya n","images":[{"img":"https://static.tigerbbs.com/f718b1732852edbe5f41671c8998e94e","width":"1125","height":"3282"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/135084783","isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":135086323,"gmtCreate":1622122619562,"gmtModify":1704179859786,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/135086323","repostId":"2138912120","repostType":4,"repost":{"id":"2138912120","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622121480,"share":"https://www.laohu8.com/m/news/2138912120?lang=&edition=full","pubTime":"2021-05-27 21:18","market":"us","language":"en","title":"GM restarting some plants hit by chips shortage","url":"https://stock-news.laohu8.com/highlight/detail?id=2138912120","media":"Reuters","summary":"May 27 (Reuters) - General Motors Co    said Thursday it will be soon be restarting production at fi","content":"<p>May 27 (Reuters) - General Motors Co    said Thursday it will be soon be restarting production at five assembly plants around the world that have been idled due to a global semiconductor chips shortage.</p><p>GM said it is restarting operations at four plants in the United States, Mexico and Canada starting next week. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> plants in Mexico will resume production next week that build the Chevrolet Equinox, GMC Terrain and Chevrolet Blazer.</p><p>Next week GM will also resume full production at its Bupyeong 1 Assembly in Korea, which had been operating at 50% capacity since April 26 and return another Korean assembly plant to two shifts.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GM restarting some plants hit by chips shortage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGM restarting some plants hit by chips shortage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-27 21:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>May 27 (Reuters) - General Motors Co    said Thursday it will be soon be restarting production at five assembly plants around the world that have been idled due to a global semiconductor chips shortage.</p><p>GM said it is restarting operations at four plants in the United States, Mexico and Canada starting next week. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> plants in Mexico will resume production next week that build the Chevrolet Equinox, GMC Terrain and Chevrolet Blazer.</p><p>Next week GM will also resume full production at its Bupyeong 1 Assembly in Korea, which had been operating at 50% capacity since April 26 and return another Korean assembly plant to two shifts.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GM":"通用汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138912120","content_text":"May 27 (Reuters) - General Motors Co    said Thursday it will be soon be restarting production at five assembly plants around the world that have been idled due to a global semiconductor chips shortage.GM said it is restarting operations at four plants in the United States, Mexico and Canada starting next week. Two plants in Mexico will resume production next week that build the Chevrolet Equinox, GMC Terrain and Chevrolet Blazer.Next week GM will also resume full production at its Bupyeong 1 Assembly in Korea, which had been operating at 50% capacity since April 26 and return another Korean assembly plant to two shifts.","news_type":1},"isVote":1,"tweetType":1,"viewCount":211,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":136463833,"gmtCreate":1622036288122,"gmtModify":1704178243284,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/136463833","repostId":"2138105101","repostType":4,"repost":{"id":"2138105101","pubTimestamp":1622034900,"share":"https://www.laohu8.com/m/news/2138105101?lang=&edition=full","pubTime":"2021-05-26 21:15","market":"us","language":"en","title":"Nasdaq seeks to remove restriction in direct listing plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2138105101","media":"StreetInsider","summary":"(Reuters) -     Nasdaq Inc asked U.S. regulators on Wednesday to remove a restriction that limits ho","content":"<p>(Reuters) -     Nasdaq Inc asked U.S. regulators on Wednesday to remove a restriction that limits how much money companies can raise through a direct listing on its stock market exchange, according to a regulatory filing reviewed by Reuters.</p><p>Direct listings allow companies to list on the stock market without a traditional and more costly initial public offering. No shares have been sold to investors in these flotations thus far, so companies have not raised any money through them.</p><p>Nasdaq's move follows the U.S. Securities and Exchange Commission's (SEC) approval last week of a Nasdaq proposal to allow companies to raise capital in a direct listing as long the shares start trading within the indicated price range set. The listing would be pulled if shares were set to trade outside that range.</p><p>Nasdaq on Wednesday asked the SEC to remove any ceiling on how the shares trade. A company's stock would not be allowed to open more than 20% below the lowest price in the price range, but there would be no restriction on how high it can trade.</p><p>\"Based on conversations with companies and their advisors, Nasdaq believes that there may be a reluctance to use the existing direct listing with a capital raise rules because of concerns about the pricing range limitation,\" Nasdaq said in the filing.</p><p>The SEC did not immediately respond to a request for comment.</p><p>In making the request to the SEC, Nasdaq is reverting to the plan it submitted to the securities watchdog last August. It amended the plan in February to bring it in line with a similar proposal from rival the New York Stock Exchange (NYSE). The SEC approved the NYSE plan in December.</p><p>Companies have been monitoring the regulatory developments but have yet to embark on a direct listing that would raise capital for them, because of the restrictions on how their shares would be allowed trade.</p><p>Advocates of the plan say it will allow companies to raise money without paying hefty underwriting fees to Wall Street banks. Some investors in private companies, such as venture capital firms, also fret that banks underprice traditional initial public offerings to create a first-day trading pop.</p><p>A growing number of companies have recently gone public through a direct listing, including big names such as analytics company Palantir Technologies, cryptocurrency exchange Coinbase Global and gaming company Roblox Corp. None of these companies raised capital in their direct listings.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nasdaq seeks to remove restriction in direct listing plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNasdaq seeks to remove restriction in direct listing plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-26 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18477227><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -     Nasdaq Inc asked U.S. regulators on Wednesday to remove a restriction that limits how much money companies can raise through a direct listing on its stock market exchange, according to...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18477227\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18477227","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138105101","content_text":"(Reuters) -     Nasdaq Inc asked U.S. regulators on Wednesday to remove a restriction that limits how much money companies can raise through a direct listing on its stock market exchange, according to a regulatory filing reviewed by Reuters.Direct listings allow companies to list on the stock market without a traditional and more costly initial public offering. No shares have been sold to investors in these flotations thus far, so companies have not raised any money through them.Nasdaq's move follows the U.S. Securities and Exchange Commission's (SEC) approval last week of a Nasdaq proposal to allow companies to raise capital in a direct listing as long the shares start trading within the indicated price range set. The listing would be pulled if shares were set to trade outside that range.Nasdaq on Wednesday asked the SEC to remove any ceiling on how the shares trade. A company's stock would not be allowed to open more than 20% below the lowest price in the price range, but there would be no restriction on how high it can trade.\"Based on conversations with companies and their advisors, Nasdaq believes that there may be a reluctance to use the existing direct listing with a capital raise rules because of concerns about the pricing range limitation,\" Nasdaq said in the filing.The SEC did not immediately respond to a request for comment.In making the request to the SEC, Nasdaq is reverting to the plan it submitted to the securities watchdog last August. It amended the plan in February to bring it in line with a similar proposal from rival the New York Stock Exchange (NYSE). The SEC approved the NYSE plan in December.Companies have been monitoring the regulatory developments but have yet to embark on a direct listing that would raise capital for them, because of the restrictions on how their shares would be allowed trade.Advocates of the plan say it will allow companies to raise money without paying hefty underwriting fees to Wall Street banks. Some investors in private companies, such as venture capital firms, also fret that banks underprice traditional initial public offerings to create a first-day trading pop.A growing number of companies have recently gone public through a direct listing, including big names such as analytics company Palantir Technologies, cryptocurrency exchange Coinbase Global and gaming company Roblox Corp. None of these companies raised capital in their direct listings.","news_type":1},"isVote":1,"tweetType":1,"viewCount":127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":130340023,"gmtCreate":1621515459662,"gmtModify":1704358880472,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/130340023","repostId":"1125677133","repostType":4,"isVote":1,"tweetType":1,"viewCount":358,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":194835491,"gmtCreate":1621352496813,"gmtModify":1704356334000,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/194835491","repostId":"2136995492","repostType":4,"repost":{"id":"2136995492","pubTimestamp":1621351887,"share":"https://www.laohu8.com/m/news/2136995492?lang=&edition=full","pubTime":"2021-05-18 23:31","market":"us","language":"en","title":"4 Reasons to Buy Electronic Arts After Its Latest Earnings Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2136995492","media":"Motley Fool","summary":"The gaming studio continues to put up consistent profits and growth.","content":"<p><b>Electronic Arts</b> (NASDAQ:EA) released its full-year 2021 earnings on May 11, delivering another year of solid growth for the gaming conglomerate. The company continues to delight shareholders by growing its top line through its long-standing franchises and up-and-coming games, while also acquiring new studios and returning cash to shareholders. Here are four reasons to buy Electronic Arts after its latest earnings report.</p>\n<h2>1. Growth of <i>Apex Legends</i></h2>\n<p>In the recent quarter, free-to-play battle royale game and <i>Fortnite</i> competitor <i>Apex Legends&nbsp;</i>hit $1 billion in lifetime bookings since its launch in 2019. CFO Blake Jorgenson mentioned that bookings (the equivalent of revenue in the gaming industry) doubled over the past 12 months, which shows the high growth the franchise is bringing to EA's business.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9f3983e379004486975fdfaf44fe4d28\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p>The free-to-play game now has over 100 million players, just launched on the Nintendo Switch, and has a mobile version coming out of beta testing soon. While most of EA's franchises are low-growth, steady cash generators like <i>FIFA</i>, <i>Madden NFL</i>, and <i>The Sims</i>, <i>Apex Legends</i> is growing at a rapid pace and shows no signs of slowing down anytime soon.</p>\n<h2>2. Recent acquisitions</h2>\n<p>EA has made two recent acquisitions. One was the purchase of U.K. studio Codemasters for $1.2 billion. Codemasters owns racing titles like <i>Dirt</i> and <i>Grid</i>, but most importantly, it brings the <i>Formula One</i> franchise under EA's roof. F1 will likely not be a blockbuster franchise as the sport is not as popular as soccer or football worldwide, but it should generate a steady stream of cash each year while also giving EA Sports the potential to expand its esports and mobile capabilities.</p>\n<p>The second acquisition was Glu Mobile for $2.1 billion. The mobile-focused studio generates over $500 million in annual bookings, so the acquisition looks like it was made at a reasonable valuation. Plus, it brings over 500 mobile game developers under EA's umbrella.</p>\n<p>Historically, EA has struggled with the mobile market. It made up only 12.6% of bookings over the last 12 months, even though it makes up 50% of the overall gaming market. If EA can leverage Glu's expertise, the company's mobile segment could grow substantially over the next few years through Glu's franchises and a revamp of EA's existing mobile titles.</p>\n<h2>3. Returning cash to shareholders</h2>\n<p>Over the last year, EA repurchased 5.6 million shares of its stock, bringing the total share count down to an estimated 287.6 million. The company has a strong history of reducing its shares outstanding (and therefore increasing the earnings attributed to remaining shareholders) as a way of returning cash to investors. Its share count has steadily come down since 2012, where it stood at 331 million, to below 288 million today.</p>\n<p>EA has also started paying a $0.17 quarterly dividend on top of its consistent buyback program. The yield is small, at about 0.5%, but with $4.5 billion in net cash (cash minus debt) and almost $2 billion in annual cash flow, EA has a clear path to grow its dividend in conjunction with its buyback program over the next decade.</p>\n<h2>4. Reasonable valuation</h2>\n<p>EA has a market cap just north of $40 billion. But if you take out the $4.5 billion in net cash -- which it won't need to fund operations -- that comes down to around $36 billion. Guidance for the next fiscal year is for $1.75 billion in operating cash flow, meaning that currently, EA's stock trades at a price-to-operating cash flow (P/OCF) of 20.5. This is not dirt cheap, but totally reasonable if you believe EA can consistently grow its business while also returning cash to shareholders through buybacks and dividends.</p>\n<p>Overall, there are a lot of reasons to like Electronic Arts prospects over the next decade. It has a high-growth franchise in <i>Apex Legends</i>, has acquired some great assets from Codemasters and Glu Mobile, and should continue to repurchase stock and pay a dividend. For these reasons and more, EA stock looks like a buy after its latest earnings report.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Reasons to Buy Electronic Arts After Its Latest Earnings Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Reasons to Buy Electronic Arts After Its Latest Earnings Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-18 23:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/18/reasons-buy-electronic-arts-after-q4-earnings/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Electronic Arts (NASDAQ:EA) released its full-year 2021 earnings on May 11, delivering another year of solid growth for the gaming conglomerate. The company continues to delight shareholders by ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/18/reasons-buy-electronic-arts-after-q4-earnings/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EA":"艺电"},"source_url":"https://www.fool.com/investing/2021/05/18/reasons-buy-electronic-arts-after-q4-earnings/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2136995492","content_text":"Electronic Arts (NASDAQ:EA) released its full-year 2021 earnings on May 11, delivering another year of solid growth for the gaming conglomerate. The company continues to delight shareholders by growing its top line through its long-standing franchises and up-and-coming games, while also acquiring new studios and returning cash to shareholders. Here are four reasons to buy Electronic Arts after its latest earnings report.\n1. Growth of Apex Legends\nIn the recent quarter, free-to-play battle royale game and Fortnite competitor Apex Legends hit $1 billion in lifetime bookings since its launch in 2019. CFO Blake Jorgenson mentioned that bookings (the equivalent of revenue in the gaming industry) doubled over the past 12 months, which shows the high growth the franchise is bringing to EA's business.\nImage source: Getty Images.\nThe free-to-play game now has over 100 million players, just launched on the Nintendo Switch, and has a mobile version coming out of beta testing soon. While most of EA's franchises are low-growth, steady cash generators like FIFA, Madden NFL, and The Sims, Apex Legends is growing at a rapid pace and shows no signs of slowing down anytime soon.\n2. Recent acquisitions\nEA has made two recent acquisitions. One was the purchase of U.K. studio Codemasters for $1.2 billion. Codemasters owns racing titles like Dirt and Grid, but most importantly, it brings the Formula One franchise under EA's roof. F1 will likely not be a blockbuster franchise as the sport is not as popular as soccer or football worldwide, but it should generate a steady stream of cash each year while also giving EA Sports the potential to expand its esports and mobile capabilities.\nThe second acquisition was Glu Mobile for $2.1 billion. The mobile-focused studio generates over $500 million in annual bookings, so the acquisition looks like it was made at a reasonable valuation. Plus, it brings over 500 mobile game developers under EA's umbrella.\nHistorically, EA has struggled with the mobile market. It made up only 12.6% of bookings over the last 12 months, even though it makes up 50% of the overall gaming market. If EA can leverage Glu's expertise, the company's mobile segment could grow substantially over the next few years through Glu's franchises and a revamp of EA's existing mobile titles.\n3. Returning cash to shareholders\nOver the last year, EA repurchased 5.6 million shares of its stock, bringing the total share count down to an estimated 287.6 million. The company has a strong history of reducing its shares outstanding (and therefore increasing the earnings attributed to remaining shareholders) as a way of returning cash to investors. Its share count has steadily come down since 2012, where it stood at 331 million, to below 288 million today.\nEA has also started paying a $0.17 quarterly dividend on top of its consistent buyback program. The yield is small, at about 0.5%, but with $4.5 billion in net cash (cash minus debt) and almost $2 billion in annual cash flow, EA has a clear path to grow its dividend in conjunction with its buyback program over the next decade.\n4. Reasonable valuation\nEA has a market cap just north of $40 billion. But if you take out the $4.5 billion in net cash -- which it won't need to fund operations -- that comes down to around $36 billion. Guidance for the next fiscal year is for $1.75 billion in operating cash flow, meaning that currently, EA's stock trades at a price-to-operating cash flow (P/OCF) of 20.5. This is not dirt cheap, but totally reasonable if you believe EA can consistently grow its business while also returning cash to shareholders through buybacks and dividends.\nOverall, there are a lot of reasons to like Electronic Arts prospects over the next decade. It has a high-growth franchise in Apex Legends, has acquired some great assets from Codemasters and Glu Mobile, and should continue to repurchase stock and pay a dividend. For these reasons and more, EA stock looks like a buy after its latest earnings report.","news_type":1},"isVote":1,"tweetType":1,"viewCount":383,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":192373380,"gmtCreate":1621153405640,"gmtModify":1704353442582,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/192373380","repostId":"1163454382","repostType":4,"repost":{"id":"1163454382","pubTimestamp":1621004581,"share":"https://www.laohu8.com/m/news/1163454382?lang=&edition=full","pubTime":"2021-05-14 23:03","market":"us","language":"en","title":"Why AMC Entertainment Stock Jumped Again Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1163454382","media":"Motley Fool","summary":"AMC investors have reason for more optimism on the heels of another capital raise.Yesterday's jump came after the company announcedit raised $428 million. First, the Centers for Disease Control and Prevention  issued a new statement on current health and safety protocols saying that fully vaccinated people can resume activities without wearing a mask or physically distancing, including indoors.This should allow theaters to open back up at full capacity and be a desirable destination for vaccinat","content":"<blockquote>\n <b>AMC investors have reason for more optimism on the heels of another capital raise.</b>\n</blockquote>\n<p><b>What happened</b></p>\n<p>A day after<b>AMC Entertainment Holdings</b>(NYSE:AMC)</p>\n<p><b>So what</b></p>\n<p>Yesterday's jump came after the company announcedit raised $428 million</p>\n<p>First, the Centers for Disease Control and Prevention (CDC) issued a new statement on current health and safety protocols saying that fully vaccinated people can resume activities without wearing a mask or physically distancing, including indoors.</p>\n<p>This should allow theaters to open back up at full capacity and be a desirable destination for vaccinated movie patrons. Also yesterday,<b>Walt Disney</b>(NYSE:DIS)announced its quarterly earnings report, and CEO Bob Chapek noted \"increased production at our studios.\" While that is a positive for theater operators, Disney also reported disappointing subscriber growth in itsstreaming services.</p>\n<p><b>Now what</b></p>\n<p>Lower streaming subscriptions could be a positive sign for the theater business. As vaccinations continue to roll out, and with the CDC now officially giving its approval to gather indoors with crowds and without masks, theater attendance may resume quickly.</p>\n<p>Vaccinations are going to drive people back to activities outside the home. Movie theaters are likely to be a favorite destination after more than a year of mostly watching at home. On the heels of another capital raise, AMC investors may be thinking this company finally has a promising path ahead.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why AMC Entertainment Stock Jumped Again Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy AMC Entertainment Stock Jumped Again Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-14 23:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/14/why-amc-entertainment-stock-jumped-again-friday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AMC investors have reason for more optimism on the heels of another capital raise.\n\nWhat happened\nA day afterAMC Entertainment Holdings(NYSE:AMC)\nSo what\nYesterday's jump came after the company ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/14/why-amc-entertainment-stock-jumped-again-friday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/05/14/why-amc-entertainment-stock-jumped-again-friday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163454382","content_text":"AMC investors have reason for more optimism on the heels of another capital raise.\n\nWhat happened\nA day afterAMC Entertainment Holdings(NYSE:AMC)\nSo what\nYesterday's jump came after the company announcedit raised $428 million\nFirst, the Centers for Disease Control and Prevention (CDC) issued a new statement on current health and safety protocols saying that fully vaccinated people can resume activities without wearing a mask or physically distancing, including indoors.\nThis should allow theaters to open back up at full capacity and be a desirable destination for vaccinated movie patrons. Also yesterday,Walt Disney(NYSE:DIS)announced its quarterly earnings report, and CEO Bob Chapek noted \"increased production at our studios.\" While that is a positive for theater operators, Disney also reported disappointing subscriber growth in itsstreaming services.\nNow what\nLower streaming subscriptions could be a positive sign for the theater business. As vaccinations continue to roll out, and with the CDC now officially giving its approval to gather indoors with crowds and without masks, theater attendance may resume quickly.\nVaccinations are going to drive people back to activities outside the home. Movie theaters are likely to be a favorite destination after more than a year of mostly watching at home. On the heels of another capital raise, AMC investors may be thinking this company finally has a promising path ahead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":214,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":196929972,"gmtCreate":1621006367596,"gmtModify":1704351921618,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Thanks for sharing","listText":"Thanks for sharing","text":"Thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/196929972","repostId":"1111018641","repostType":4,"isVote":1,"tweetType":1,"viewCount":187,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":191070754,"gmtCreate":1620830434978,"gmtModify":1704349072893,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SBUX\">$Starbucks(SBUX)$</a>dhisndf","listText":"<a href=\"https://laohu8.com/S/SBUX\">$Starbucks(SBUX)$</a>dhisndf","text":"$Starbucks(SBUX)$dhisndf","images":[{"img":"https://static.tigerbbs.com/727543736fc358cc12dc1929f8d98814","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/191070754","isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":191054560,"gmtCreate":1620829586050,"gmtModify":1704349056534,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Uppppzz&nbsp;","listText":"Uppppzz&nbsp;","text":"Uppppzz","images":[{"img":"https://static.tigerbbs.com/49fdd8247005beda8b462ba7c63653b9","width":"1125","height":"2874"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/191054560","isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":134326282,"gmtCreate":1622209102946,"gmtModify":1704181507874,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/134326282","repostId":"2138107027","repostType":4,"repost":{"id":"2138107027","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1622207700,"share":"https://www.laohu8.com/m/news/2138107027?lang=&edition=full","pubTime":"2021-05-28 21:15","market":"us","language":"en","title":"HSBC Shareholders Back Co's Net Zero Commitments","url":"https://stock-news.laohu8.com/highlight/detail?id=2138107027","media":"Reuters","summary":"HSBC Holdings Plc:Hsbc Holdings Plc - Shareholders Back Hsbc’S Net Zero Commitments.Hsbc - Special R","content":"<p><a href=\"https://laohu8.com/S/HBCYF\">HSBC Holdings Plc</a>:Hsbc Holdings Plc - Shareholders Back Hsbc’S Net Zero Commitments.Hsbc - Special Resolution On Climate Change Was Approved At Our Annual General Meeting..</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HSBC Shareholders Back Co's Net Zero Commitments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHSBC Shareholders Back Co's Net Zero Commitments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-28 21:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><a href=\"https://laohu8.com/S/HBCYF\">HSBC Holdings Plc</a>:Hsbc Holdings Plc - Shareholders Back Hsbc’S Net Zero Commitments.Hsbc - Special Resolution On Climate Change Was Approved At Our Annual General Meeting..</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HSBC":"汇丰"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138107027","content_text":"HSBC Holdings Plc:Hsbc Holdings Plc - Shareholders Back Hsbc’S Net Zero Commitments.Hsbc - Special Resolution On Climate Change Was Approved At Our Annual General Meeting..","news_type":1},"isVote":1,"tweetType":1,"viewCount":246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":130340023,"gmtCreate":1621515459662,"gmtModify":1704358880472,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/130340023","repostId":"1125677133","repostType":4,"isVote":1,"tweetType":1,"viewCount":358,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":118594655,"gmtCreate":1622736920377,"gmtModify":1704190239905,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/118594655","repostId":"2140247164","repostType":4,"repost":{"id":"2140247164","pubTimestamp":1622730037,"share":"https://www.laohu8.com/m/news/2140247164?lang=&edition=full","pubTime":"2021-06-03 22:20","market":"us","language":"en","title":"Is It Time to Buy the Dow Jones' 3 Worst Performing May Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2140247164","media":"Motley Fool","summary":"These are the last three names you want to see weakness from right now.","content":"<p>Most of the time, one stock's single-digit percentage rise or fall in any given month isn't all that interesting. It happens. Stocks are supposed to ebb and flow.</p>\n<p>That's what makes last month's small sell-offs from <b>Apple</b> (NASDAQ:AAPL), <b><a href=\"https://laohu8.com/S/V\">Visa</a></b> (NYSE:V), and<b> Walt Disney </b>(NYSE:DIS) so unremarkable. While these Dow components lost more ground than any of their Dow counterparts, the worst-performing of these -- Apple -- still only fell 5% in May. It remains the king of consumer tech, and plenty of investors are using the pullback as a buying opportunity.</p>\n<p>Before you follow suit, however, take a step back and look at the bigger dynamic. The Dow's three biggest losers in May are not only the names most likely to benefit from a post-pandemic reopening, they're also the same very names that have led the<b> Dow Jones Industrial Average</b> (DJINDICES:^DJI) higher over the course of the past several months. To see these leaders suddenly turn into laggards is a hint of a big shift in investor sentiment that just might work against the broad market for a while.</p>\n<h2>From leaders to laggards</h2>\n<p>Although the Dow advanced 2% last month, Apple, Visa, and Disney shares fell 5%, 4%, and 3%, respectively, in May, holding the Dow Jones Industrial Average back more than any of the other names that make up the index. But all the figures are fairly modest.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c7dbf02119c7b8c7af6ed661b0dc7519\" tg-width=\"700\" tg-height=\"495\"><span>Image source: Getty Images.</span></p>\n<p>Read between the lines, though: Something's changed.</p>\n<p>Sure, you could argue that Disney's disappointing subscriber growth for its Disney+ streaming service is the culprit for its weakness. The thing is, Disney shares were already peeling back from their March peak when that news hit last month. Visa's rally lasted all the way through its late-April peak at a record high of $237.50 before it began to weaken, largely in response to last quarter's results. While hardly horrifying, the 2% slide of its top and bottom lines loosely suggests whatever reopening benefit the payment company is going to reap has already been mostly reaped. And as for Apple, its all-time peak came all the way back in January. While its fiscal second-quarter numbers posted at the end of April were nothing less than stellar (sales were up 54% year over year to reach a new Q2 record), the market chose to see the proverbial glass as half empty rather than half full. The company also says it's feeling the impact of the chip shortage.</p>\n<p>Yet none of these are the sorts of challenges that would have dragged these stocks lower in the recent past. To see three of the Dow's very best performers start to lag simultaneously is telling, not so much about these three companies, but about investors' broad perceptions of the market's current health.</p>\n<h2>Right on cue</h2>\n<p>And curiously, these clues are taking shape exactly when you'd expect them to.</p>\n<p>While most long-term investors shouldn't be timing their entries and exits to correspond with what looks like the market's lows and highs, it would be naive to ignore how the major indexes entered this year's \"sell in May\" period well above where they'd normally be. As of the end of April the <b>S&amp;P 500</b> was up 11.5% from the end of 2020, when it would normally be up on the order of 3.4%. Last month's weakness filled in some of that gap, but most of it remains unfilled.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F629163%2F060121-sp500-average.png&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"469\"><span>Data source: Thomson Reuters. Chart by author.</span></p>\n<p>And lest you think this year's bullish start is merely the back end of last year's rebound from a strong sell-off when the coronavirus pandemic began in the United States, it isn't.</p>\n<p>Although the S&amp;P 500 was down as much as 35% in early 2020, it ended that year 16% higher than where it started it. This year's big gains simply move the market deeper into overbought territory, further ripening it for the sort of profit taking we're seeing take shape now. With influential names like Apple and Disney setting the tone, other stocks may soon mirror their weakness.</p>\n<h2>A simple answer</h2>\n<p>So to answer the question, no, the Dow's May laggards aren't buys here -- at least not yet.</p>\n<p>That doesn't necessarily make them sells if you currently own them, particularly if there are tax consequences of selling. All three are still fine companies with a bright future. The red flags waving here are simply pointing to weakness mostly stemming from profit taking, but don't signal the onset of a full-blown bear market.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the Dow Jones' 3 Worst Performing May Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the Dow Jones' 3 Worst Performing May Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 22:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/is-it-time-to-buy-the-dow-jones-3-worst-performing/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Most of the time, one stock's single-digit percentage rise or fall in any given month isn't all that interesting. It happens. Stocks are supposed to ebb and flow.\nThat's what makes last month's small ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/is-it-time-to-buy-the-dow-jones-3-worst-performing/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIS":"迪士尼","AAPL":"苹果","V":"Visa"},"source_url":"https://www.fool.com/investing/2021/06/03/is-it-time-to-buy-the-dow-jones-3-worst-performing/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140247164","content_text":"Most of the time, one stock's single-digit percentage rise or fall in any given month isn't all that interesting. It happens. Stocks are supposed to ebb and flow.\nThat's what makes last month's small sell-offs from Apple (NASDAQ:AAPL), Visa (NYSE:V), and Walt Disney (NYSE:DIS) so unremarkable. While these Dow components lost more ground than any of their Dow counterparts, the worst-performing of these -- Apple -- still only fell 5% in May. It remains the king of consumer tech, and plenty of investors are using the pullback as a buying opportunity.\nBefore you follow suit, however, take a step back and look at the bigger dynamic. The Dow's three biggest losers in May are not only the names most likely to benefit from a post-pandemic reopening, they're also the same very names that have led the Dow Jones Industrial Average (DJINDICES:^DJI) higher over the course of the past several months. To see these leaders suddenly turn into laggards is a hint of a big shift in investor sentiment that just might work against the broad market for a while.\nFrom leaders to laggards\nAlthough the Dow advanced 2% last month, Apple, Visa, and Disney shares fell 5%, 4%, and 3%, respectively, in May, holding the Dow Jones Industrial Average back more than any of the other names that make up the index. But all the figures are fairly modest.\nImage source: Getty Images.\nRead between the lines, though: Something's changed.\nSure, you could argue that Disney's disappointing subscriber growth for its Disney+ streaming service is the culprit for its weakness. The thing is, Disney shares were already peeling back from their March peak when that news hit last month. Visa's rally lasted all the way through its late-April peak at a record high of $237.50 before it began to weaken, largely in response to last quarter's results. While hardly horrifying, the 2% slide of its top and bottom lines loosely suggests whatever reopening benefit the payment company is going to reap has already been mostly reaped. And as for Apple, its all-time peak came all the way back in January. While its fiscal second-quarter numbers posted at the end of April were nothing less than stellar (sales were up 54% year over year to reach a new Q2 record), the market chose to see the proverbial glass as half empty rather than half full. The company also says it's feeling the impact of the chip shortage.\nYet none of these are the sorts of challenges that would have dragged these stocks lower in the recent past. To see three of the Dow's very best performers start to lag simultaneously is telling, not so much about these three companies, but about investors' broad perceptions of the market's current health.\nRight on cue\nAnd curiously, these clues are taking shape exactly when you'd expect them to.\nWhile most long-term investors shouldn't be timing their entries and exits to correspond with what looks like the market's lows and highs, it would be naive to ignore how the major indexes entered this year's \"sell in May\" period well above where they'd normally be. As of the end of April the S&P 500 was up 11.5% from the end of 2020, when it would normally be up on the order of 3.4%. Last month's weakness filled in some of that gap, but most of it remains unfilled.\nData source: Thomson Reuters. Chart by author.\nAnd lest you think this year's bullish start is merely the back end of last year's rebound from a strong sell-off when the coronavirus pandemic began in the United States, it isn't.\nAlthough the S&P 500 was down as much as 35% in early 2020, it ended that year 16% higher than where it started it. This year's big gains simply move the market deeper into overbought territory, further ripening it for the sort of profit taking we're seeing take shape now. With influential names like Apple and Disney setting the tone, other stocks may soon mirror their weakness.\nA simple answer\nSo to answer the question, no, the Dow's May laggards aren't buys here -- at least not yet.\nThat doesn't necessarily make them sells if you currently own them, particularly if there are tax consequences of selling. All three are still fine companies with a bright future. The red flags waving here are simply pointing to weakness mostly stemming from profit taking, but don't signal the onset of a full-blown bear market.","news_type":1},"isVote":1,"tweetType":1,"viewCount":229,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":196929972,"gmtCreate":1621006367596,"gmtModify":1704351921618,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Thanks for sharing","listText":"Thanks for sharing","text":"Thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/196929972","repostId":"1111018641","repostType":4,"repost":{"id":"1111018641","pubTimestamp":1621000588,"share":"https://www.laohu8.com/m/news/1111018641?lang=&edition=full","pubTime":"2021-05-14 21:56","market":"us","language":"en","title":"Opinion: Why any stock market rally right now will be quick","url":"https://stock-news.laohu8.com/highlight/detail?id=1111018641","media":"MarketWatch","summary":"Market-timers are running with the bulls but quick to turn bearish.\n\nContrarian investors suspect th","content":"<blockquote>\n <b>Market-timers are running with the bulls but quick to turn bearish.</b>\n</blockquote>\n<p>Contrarian investors suspect that the stock market’s recent decline has run its course — for now.</p>\n<p>That’s because these market timers, especially those who focus on the NasdaqNDX,1.07%market in particular, have become sufficiently bearish that the short-term path of least resistance has turned up. Still, it’s not clear that any new rally will have much lasting power. An even more serious U.S. market decline cannot be ruled out over the coming couple of months.</p>\n<p>For now, the recent decline appears to have been quite modest by historical standards, smaller even than what satisfies the semi-official definition of a correction as a 10% decline. Before Thursday’s big rally, the Dow Jones Industrial AverageDJIA,0.85%had fallen around 1,200 points from its previous all-time high, or 3.4%. The S&amp;P 500SPX,0.98%was 4.0% below its high, and the Nasdaq CompositeCOMP,1.13%was down 7.8%.</p>\n<p>Consider how the Nasdaq-focused market timers reacted to these declines. As you can see from the chart below, their average recommended equity exposure (as represented by the Hulbert Nasdaq Newsletter Sentiment Index, or HNNSI) fell to minus 10.7%. That means that the Nasdaq-focused market timers are now recommending that their clients allocate an average of 10.7% of their equity trading portfolios to going short. As recently as April 29, this average exposure level stood at plus 83.6%.</p>\n<p><img src=\"https://static.tigerbbs.com/d550f647619d600d419397967f7bb778\" tg-width=\"1260\" tg-height=\"928\"></p>\n<p>That reflects a remarkably quick rush for the exits — 94.3 percentage points in just 10 trading sessions. In fact, out of the 5,000+ trading days since 2000, there have been only 18 — 0.3% — in which the HNNSI’s decline over the trailing 10 days was greater.</p>\n<p>To appreciate the contrarian significance of this, consider that, on average following those past few occasions when the HNNSI declined by this much and this fast, the Nasdaq Composite was 5.3% higher in one month’s time.</p>\n<p>Why, then, haven’t the contrarians become more bullish? The answer is also evident in the chart: The HNNSI’s plunge over the past 10 days stopped well short of the excessive bearish zone, defined as being in the bottom 10% of the historical distribution. That zone is represented by the beige-shaded box at the bottom of the chart.</p>\n<p>The last time the HNNSI fell into that zone was in March 2020. That was when the market’s “wall of worry” became incredibly strong and was able to support an impressive rally. That wall today is not as strong.</p>\n<p>The sentiment picture that the recent data are painting shows the market timers to be trigger-happy. They are quick to jump on the bullish bandwagon when the market rallies, and then jump on the bearish bandwagon when the market declines. As a result, both rallies and declines tend to be short-lived.</p>\n<p>A longer-lasting rally will require more extreme bearishness among the market timers, and for them to stubbornly hold onto their bearishness in the wake of the rally’s initial liftoff. Except for that to happen, the market to itself most likely would have to suffer a worse decline than we’ve experienced in recent days. In the meantime, enjoy this rally — while it lasts.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Opinion: Why any stock market rally right now will be quick</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOpinion: Why any stock market rally right now will be quick\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-14 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/why-any-stock-market-rally-right-now-will-be-quick-11620958836?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Market-timers are running with the bulls but quick to turn bearish.\n\nContrarian investors suspect that the stock market’s recent decline has run its course — for now.\nThat’s because these market ...</p>\n\n<a href=\"https://www.marketwatch.com/story/why-any-stock-market-rally-right-now-will-be-quick-11620958836?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","SPY":"标普500ETF"},"source_url":"https://www.marketwatch.com/story/why-any-stock-market-rally-right-now-will-be-quick-11620958836?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111018641","content_text":"Market-timers are running with the bulls but quick to turn bearish.\n\nContrarian investors suspect that the stock market’s recent decline has run its course — for now.\nThat’s because these market timers, especially those who focus on the NasdaqNDX,1.07%market in particular, have become sufficiently bearish that the short-term path of least resistance has turned up. Still, it’s not clear that any new rally will have much lasting power. An even more serious U.S. market decline cannot be ruled out over the coming couple of months.\nFor now, the recent decline appears to have been quite modest by historical standards, smaller even than what satisfies the semi-official definition of a correction as a 10% decline. Before Thursday’s big rally, the Dow Jones Industrial AverageDJIA,0.85%had fallen around 1,200 points from its previous all-time high, or 3.4%. The S&P 500SPX,0.98%was 4.0% below its high, and the Nasdaq CompositeCOMP,1.13%was down 7.8%.\nConsider how the Nasdaq-focused market timers reacted to these declines. As you can see from the chart below, their average recommended equity exposure (as represented by the Hulbert Nasdaq Newsletter Sentiment Index, or HNNSI) fell to minus 10.7%. That means that the Nasdaq-focused market timers are now recommending that their clients allocate an average of 10.7% of their equity trading portfolios to going short. As recently as April 29, this average exposure level stood at plus 83.6%.\n\nThat reflects a remarkably quick rush for the exits — 94.3 percentage points in just 10 trading sessions. In fact, out of the 5,000+ trading days since 2000, there have been only 18 — 0.3% — in which the HNNSI’s decline over the trailing 10 days was greater.\nTo appreciate the contrarian significance of this, consider that, on average following those past few occasions when the HNNSI declined by this much and this fast, the Nasdaq Composite was 5.3% higher in one month’s time.\nWhy, then, haven’t the contrarians become more bullish? The answer is also evident in the chart: The HNNSI’s plunge over the past 10 days stopped well short of the excessive bearish zone, defined as being in the bottom 10% of the historical distribution. That zone is represented by the beige-shaded box at the bottom of the chart.\nThe last time the HNNSI fell into that zone was in March 2020. That was when the market’s “wall of worry” became incredibly strong and was able to support an impressive rally. That wall today is not as strong.\nThe sentiment picture that the recent data are painting shows the market timers to be trigger-happy. They are quick to jump on the bullish bandwagon when the market rallies, and then jump on the bearish bandwagon when the market declines. As a result, both rallies and declines tend to be short-lived.\nA longer-lasting rally will require more extreme bearishness among the market timers, and for them to stubbornly hold onto their bearishness in the wake of the rally’s initial liftoff. Except for that to happen, the market to itself most likely would have to suffer a worse decline than we’ve experienced in recent days. In the meantime, enjoy this rally — while it lasts.","news_type":1},"isVote":1,"tweetType":1,"viewCount":187,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119454643,"gmtCreate":1622560637282,"gmtModify":1704186405956,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/119454643","repostId":"2140617694","repostType":4,"repost":{"id":"2140617694","pubTimestamp":1622560398,"share":"https://www.laohu8.com/m/news/2140617694?lang=&edition=full","pubTime":"2021-06-01 23:13","market":"us","language":"en","title":"The Top 50 Robinhood Stocks in June","url":"https://stock-news.laohu8.com/highlight/detail?id=2140617694","media":"Motley Fool","summary":"Millennial investors can't stop buying into these companies.","content":"<p>Volatility is always present in the stock market, but it's been especially prominent since February 2020. Though patience has, once again, paid off for investors, their gains have come after the benchmark <b>S&amp;P 500</b> lost 34% of its value in less than five weeks during the first quarter of 2020.</p>\n<p>Some investors absolutely shy away when heightened volatility rears its head. But that's not what we've witnessed from retail investors.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/99b3853458b2424e2901821012f5502f\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p>Even though retail investors have been putting their money to work on Wall Street for more than a century, they used the wild volatility on Wall Street over the past 16 months as their cue to really ramp up their buying. How do we know this? Just take a look at online investing app Robinhood, which gained approximately 3 million new users last year.</p>\n<p>Millennial investors have found a home at Robinhood for a bevy of reasons. The app doesn't charge commissions for buying or selling on major exchanges, and it allows fractional shares&nbsp;for a number of securities. The company even awards new members with free shares of stock.</p>\n<p>While it's fantastic to see young investors putting their money to work in the greatest wealth creator on the planet, it's also disturbing to see what they've been buying. Instead of taking the tried-and-true long-term investing approach, many are chasing momentum plays, penny stocks, and companies with poor operating performance.</p>\n<p>Don't believe me? Here are the 50 most-held stocks on Robinhood's leaderboard as we enter June:</p>\n<table width=\"492\">\n <thead>\n  <tr>\n   <th>Company</th>\n   <th>Company</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>1. <b>Tesla </b>(NASDAQ:TSLA)</td>\n   <td>26. <b>OrganiGram Holdings</b></td>\n  </tr>\n  <tr>\n   <td>2. <b>Apple&nbsp;</b></td>\n   <td>27. <b>Bank of America</b></td>\n  </tr>\n  <tr>\n   <td>3. <b>AMC Entertainment Holdings</b> (NYSE:AMC)</td>\n   <td>28. <b>Coinbase Global</b></td>\n  </tr>\n  <tr>\n   <td>4. <b>Sundial Growers</b> (NASDAQ:SNDL)</td>\n   <td>29. <b>Tilray</b></td>\n  </tr>\n  <tr>\n   <td>5. <b>Ford Motor</b></td>\n   <td>30. <b><a href=\"https://laohu8.com/S/FB\">Facebook</a></b></td>\n  </tr>\n  <tr>\n   <td>6. <b>General Electric</b></td>\n   <td>31. <b>Canopy Growth</b> (NASDAQ:CGC)</td>\n  </tr>\n  <tr>\n   <td>7. <b>NIO&nbsp;</b></td>\n   <td>32. <b>Advanced Micro Devices</b></td>\n  </tr>\n  <tr>\n   <td>8. <b>Walt Disney</b></td>\n   <td>33. <b><a href=\"https://laohu8.com/S/TWTR\">Twitter</a></b></td>\n  </tr>\n  <tr>\n   <td>9. <b>Microsoft</b></td>\n   <td>34. <b>Starbucks</b> (NASDAQ:SBUX)</td>\n  </tr>\n  <tr>\n   <td>10. <b>Amazon&nbsp;</b></td>\n   <td>35. <b>Moderna</b></td>\n  </tr>\n  <tr>\n   <td>11. <b>American Airlines Group</b></td>\n   <td>36. <b>AT&amp;T</b></td>\n  </tr>\n  <tr>\n   <td>12. <b>Plug Power</b></td>\n   <td>37. <b>FuelCell Energy</b></td>\n  </tr>\n  <tr>\n   <td>13. <b>Nokia&nbsp;</b></td>\n   <td>38. <b>Virgin Galactic Holdings&nbsp;</b></td>\n  </tr>\n  <tr>\n   <td>14. <b>Pfizer&nbsp;</b></td>\n   <td>39. <b>Ideanomics&nbsp;</b></td>\n  </tr>\n  <tr>\n   <td>15. <b>Aurora Cannabis</b> (NASDAQ:ACB)</td>\n   <td>40. <b>Norwegian Cruise Line Holdings</b></td>\n  </tr>\n  <tr>\n   <td>16. <b>Carnival</b></td>\n   <td>41. <b>Vanguard S&amp;P 500 ETF</b></td>\n  </tr>\n  <tr>\n   <td>17. <b>GameStop</b> (NYSE:GME)</td>\n   <td>42. <b>Coca-Cola</b></td>\n  </tr>\n  <tr>\n   <td>18. <b>Zomedica</b> (NYSEMKT:ZOM)</td>\n   <td>43. <b>General Motors</b></td>\n  </tr>\n  <tr>\n   <td>19. <b><a href=\"https://laohu8.com/S/GPRO\">GoPro</a>&nbsp;</b></td>\n   <td>44. <b>NVIDIA</b></td>\n  </tr>\n  <tr>\n   <td>20. <b>Palantir Technologies</b></td>\n   <td>45. <b>SPDR S&amp;P 500 ETF</b></td>\n  </tr>\n  <tr>\n   <td>21. <b><a href=\"https://laohu8.com/S/CCC.U\">Churchill Capital</a></b></td>\n   <td>46. <b>United Airlines Holdings</b></td>\n  </tr>\n  <tr>\n   <td>22. <b>Delta Air Lines</b></td>\n   <td>47. <b>Uber Technologies</b></td>\n  </tr>\n  <tr>\n   <td>23. <b>Snap&nbsp;</b></td>\n   <td>48. <b><a href=\"https://laohu8.com/S/ZNGA\">Zynga</a></b></td>\n  </tr>\n  <tr>\n   <td>24. <b>Netflix&nbsp;</b></td>\n   <td>49. <b>Boeing</b></td>\n  </tr>\n  <tr>\n   <td>25. <b>Alibaba Group Holding</b></td>\n   <td>50. <b>Workhorse Group</b></td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: Robinhood, as of May 28, 2021.</p>\n<h2>Meme-mania doesn't stop</h2>\n<p>With retail investors acting as the catalyst behind the meme stock craze (meme stocks are companies lauded for their social media popularity, not their fundamentals), it should come as no surprise that companies like AMC Entertainment, GameStop, and Sundial Growers are among the most-held on Robinhood.</p>\n<p>AMC, GameStop, and Sundial were some of the most heavily short-sold companies earlier this year, which made them logical targets by investors on Reddit who were looking for short-squeeze opportunities. Though we witnessed these squeezes take place in January and February, the recent trading in these names looks to be more hype or mania than short-covering.</p>\n<p>History is pretty clear that hype-driven stocks will eventually have the rug pulled out from under them. AMC, for example, is going to struggle just to service its more than $5.4 billion in corporate debt and doesn't appear to have a chance to pay back what comes due in 2026. It also has $473 million in deferred rent obligations to contend with.</p>\n<p>As for GameStop, it boasts a healthy net cash position following a recent share offering. But it was very late in transitioning to digital gaming, and as a result will see its sales go nowhere for years to come. GameStop's core strategy for the time being is to keep closing physical stores to cut down on operating expenses.</p>\n<p>In sum, meme stocks are bad news.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/86c5f70d97c3ea9f633e0f2dbad565ba\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Penny for your thoughts</h2>\n<p>Robinhood investors have also demonstrated that they love penny stocks. Sundial Growers and Zomedica are two of the 18 most-held stocks on the platform, yet both can be purchased for under $1 a share.</p>\n<p>Psychologically, young and/or novice investors believe that owning more shares of stock will give them a better chance to make a lot of money. There's also the belief that it's easier to double a stock from $1 a share to $2 than, say, $100 to $200. But the reality is that penny stocks almost always trade at a low share price for very good reasons.</p>\n<p>In the case of pot stock Sundial Growers, it's because the company's management team can't stop drowning its investors in share offerings. Earlier this year, the company's board OK'd an additional $800 million at-the-market share offering. Since the end of September, more than 1.35 billion shares have been issued. With 1.86 billion shares now outstanding, Sundial has almost no chance of ever generating meaningful earnings per share, or perhaps even remaining listed on the <b>Nasdaq</b>&nbsp;exchange.</p>\n<p>As for veterinary health company Zomedica, it only began commercializing its first product in mid-March. Shares are currently valued at close to 40 times sales looking three years into the future. Though it does have a healthy cash position, Zomedica has buried its investors with share offerings and is closing in on 1 billion shares outstanding.</p>\n<p>Penny stocks are rarely cheap.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5811406aed4001edc942cb25310a21cf\" tg-width=\"700\" tg-height=\"467\"><span>Image source: Getty Images.</span></p>\n<h2>\"Merry-juana\"</h2>\n<p>Another trend you'll note about millennial investors is that they really love the prospects for marijuana stocks. In this respect, I agree with them.</p>\n<p>Unfortunately, Robinhood is shortchanging its users in the cannabis department. Since the trading platform won't allow its users to buy and sell stocks listed on the over-the-counter exchange, and U.S. pot stocks can't list on major exchanges due to cannabis being illicit at the federal level, Robinhood users are stuck buying Canadian weed stocks. To put things as nicely as possible, the Canadian pot stocks have been a disaster.</p>\n<p>Aurora Cannabis, which at <a href=\"https://laohu8.com/S/AONE\">one</a> time was the most-held stock on Robinhood, has been burying its shareholders in dilution for years. It used its stock as collateral for around a dozen deals and grossly overpaid for all of its acquisitions. Even with legal Canadian weed sales climbing, Aurora's top line has been stuck in neutral or gone in reverse.</p>\n<p>Canopy Growth is another popular marijuana stock that's been an utter disappointment. The company's cash pile has dwindled significantly over the past couple of years, and Canopy is still nowhere close to generating a profit, even after closing two large greenhouses in British Columbia.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/11b7b594784b441dbeb82fcdb187aac3\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Starbucks.</span></p>\n<h2>Brand-name companies are popular with millennials</h2>\n<p>Lastly, you'll note that among the meme stocks, pot stocks, and penny stocks, millennial investors have also piled into brand-name companies that they're familiar with or regularly engage with.</p>\n<p>For instance, electric-vehicle (EV) manufacturer Tesla has supplanted Apple as the most-held stock in the Robinhood universe. Generally speaking, the desire to take action against climate change increases the younger someone is. Motivated young investors who want to see positive climate action taken, and who have a favorable view of CEO Elon Musk, have flocked to Tesla. In kind, Tesla's production numbers have risen significantly, and could near 800,000 EVs in 2021.</p>\n<p>Coffee giant Starbucks has also been rising up the leaderboard in recent months. It has used its mobile app and rewards as a means to keep the younger generation loyal to its brand. It has also introduced an array of healthier lunches and snack options to improve foot traffic. It definitely doesn't hurt that Starbucks is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most-recognized brands in the world.</p>\n<p>Brand-name companies that can engage with young investors are always a good bet to work their way onto Robinhood's leaderboard.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Top 50 Robinhood Stocks in June</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Top 50 Robinhood Stocks in June\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 23:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/01/the-top-50-robinhood-stocks-in-june/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Volatility is always present in the stock market, but it's been especially prominent since February 2020. Though patience has, once again, paid off for investors, their gains have come after the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/01/the-top-50-robinhood-stocks-in-june/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIS":"迪士尼","T":"美国电话电报","DAL":"达美航空","SPCE":"维珍银河","BA":"波音","SNDL":"SNDL Inc.","F":"福特汽车","TLRY":"Tilray Inc.","BABA":"阿里巴巴","OGI":"ORGANIGRAM HOLD","CCL":"嘉年华邮轮","TSLA":"特斯拉","AMC":"AMC院线","NIO":"蔚来","GM":"通用汽车","NVDA":"英伟达","CGC":"Canopy Growth Corporation","SNAP":"Snap Inc","UBER":"优步","PFE":"辉瑞","UAL":"联合大陆航空","ZOM":"Zomedica Pharmaceuticals Corp.","WKHS":"Workhorse Group, Inc.","MSFT":"微软","ACB":"奥罗拉大麻公司","GME":"游戏驿站","NFLX":"奈飞","BAC":"美国银行","PLTR":"Palantir Technologies Inc.","KO":"可口可乐","SBUX":"星巴克","FCEL":"燃料电池能源","GE":"GE航空航天","GPRO":"GoPro","NOK":"诺基亚","COIN":"Coinbase Global, Inc.","AMD":"美国超微公司","TWTR":"Twitter","PLUG":"普拉格能源","AAPL":"苹果","MRNA":"Moderna, Inc.","AAL":"美国航空"},"source_url":"https://www.fool.com/investing/2021/06/01/the-top-50-robinhood-stocks-in-june/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140617694","content_text":"Volatility is always present in the stock market, but it's been especially prominent since February 2020. Though patience has, once again, paid off for investors, their gains have come after the benchmark S&P 500 lost 34% of its value in less than five weeks during the first quarter of 2020.\nSome investors absolutely shy away when heightened volatility rears its head. But that's not what we've witnessed from retail investors.\nImage source: Getty Images.\nEven though retail investors have been putting their money to work on Wall Street for more than a century, they used the wild volatility on Wall Street over the past 16 months as their cue to really ramp up their buying. How do we know this? Just take a look at online investing app Robinhood, which gained approximately 3 million new users last year.\nMillennial investors have found a home at Robinhood for a bevy of reasons. The app doesn't charge commissions for buying or selling on major exchanges, and it allows fractional shares for a number of securities. The company even awards new members with free shares of stock.\nWhile it's fantastic to see young investors putting their money to work in the greatest wealth creator on the planet, it's also disturbing to see what they've been buying. Instead of taking the tried-and-true long-term investing approach, many are chasing momentum plays, penny stocks, and companies with poor operating performance.\nDon't believe me? Here are the 50 most-held stocks on Robinhood's leaderboard as we enter June:\n\n\n\nCompany\nCompany\n\n\n\n\n1. Tesla (NASDAQ:TSLA)\n26. OrganiGram Holdings\n\n\n2. Apple \n27. Bank of America\n\n\n3. AMC Entertainment Holdings (NYSE:AMC)\n28. Coinbase Global\n\n\n4. Sundial Growers (NASDAQ:SNDL)\n29. Tilray\n\n\n5. Ford Motor\n30. Facebook\n\n\n6. General Electric\n31. Canopy Growth (NASDAQ:CGC)\n\n\n7. NIO \n32. Advanced Micro Devices\n\n\n8. Walt Disney\n33. Twitter\n\n\n9. Microsoft\n34. Starbucks (NASDAQ:SBUX)\n\n\n10. Amazon \n35. Moderna\n\n\n11. American Airlines Group\n36. AT&T\n\n\n12. Plug Power\n37. FuelCell Energy\n\n\n13. Nokia \n38. Virgin Galactic Holdings \n\n\n14. Pfizer \n39. Ideanomics \n\n\n15. Aurora Cannabis (NASDAQ:ACB)\n40. Norwegian Cruise Line Holdings\n\n\n16. Carnival\n41. Vanguard S&P 500 ETF\n\n\n17. GameStop (NYSE:GME)\n42. Coca-Cola\n\n\n18. Zomedica (NYSEMKT:ZOM)\n43. General Motors\n\n\n19. GoPro \n44. NVIDIA\n\n\n20. Palantir Technologies\n45. SPDR S&P 500 ETF\n\n\n21. Churchill Capital\n46. United Airlines Holdings\n\n\n22. Delta Air Lines\n47. Uber Technologies\n\n\n23. Snap \n48. Zynga\n\n\n24. Netflix \n49. Boeing\n\n\n25. Alibaba Group Holding\n50. Workhorse Group\n\n\n\nData source: Robinhood, as of May 28, 2021.\nMeme-mania doesn't stop\nWith retail investors acting as the catalyst behind the meme stock craze (meme stocks are companies lauded for their social media popularity, not their fundamentals), it should come as no surprise that companies like AMC Entertainment, GameStop, and Sundial Growers are among the most-held on Robinhood.\nAMC, GameStop, and Sundial were some of the most heavily short-sold companies earlier this year, which made them logical targets by investors on Reddit who were looking for short-squeeze opportunities. Though we witnessed these squeezes take place in January and February, the recent trading in these names looks to be more hype or mania than short-covering.\nHistory is pretty clear that hype-driven stocks will eventually have the rug pulled out from under them. AMC, for example, is going to struggle just to service its more than $5.4 billion in corporate debt and doesn't appear to have a chance to pay back what comes due in 2026. It also has $473 million in deferred rent obligations to contend with.\nAs for GameStop, it boasts a healthy net cash position following a recent share offering. But it was very late in transitioning to digital gaming, and as a result will see its sales go nowhere for years to come. GameStop's core strategy for the time being is to keep closing physical stores to cut down on operating expenses.\nIn sum, meme stocks are bad news.\nImage source: Getty Images.\nPenny for your thoughts\nRobinhood investors have also demonstrated that they love penny stocks. Sundial Growers and Zomedica are two of the 18 most-held stocks on the platform, yet both can be purchased for under $1 a share.\nPsychologically, young and/or novice investors believe that owning more shares of stock will give them a better chance to make a lot of money. There's also the belief that it's easier to double a stock from $1 a share to $2 than, say, $100 to $200. But the reality is that penny stocks almost always trade at a low share price for very good reasons.\nIn the case of pot stock Sundial Growers, it's because the company's management team can't stop drowning its investors in share offerings. Earlier this year, the company's board OK'd an additional $800 million at-the-market share offering. Since the end of September, more than 1.35 billion shares have been issued. With 1.86 billion shares now outstanding, Sundial has almost no chance of ever generating meaningful earnings per share, or perhaps even remaining listed on the Nasdaq exchange.\nAs for veterinary health company Zomedica, it only began commercializing its first product in mid-March. Shares are currently valued at close to 40 times sales looking three years into the future. Though it does have a healthy cash position, Zomedica has buried its investors with share offerings and is closing in on 1 billion shares outstanding.\nPenny stocks are rarely cheap.\nImage source: Getty Images.\n\"Merry-juana\"\nAnother trend you'll note about millennial investors is that they really love the prospects for marijuana stocks. In this respect, I agree with them.\nUnfortunately, Robinhood is shortchanging its users in the cannabis department. Since the trading platform won't allow its users to buy and sell stocks listed on the over-the-counter exchange, and U.S. pot stocks can't list on major exchanges due to cannabis being illicit at the federal level, Robinhood users are stuck buying Canadian weed stocks. To put things as nicely as possible, the Canadian pot stocks have been a disaster.\nAurora Cannabis, which at one time was the most-held stock on Robinhood, has been burying its shareholders in dilution for years. It used its stock as collateral for around a dozen deals and grossly overpaid for all of its acquisitions. Even with legal Canadian weed sales climbing, Aurora's top line has been stuck in neutral or gone in reverse.\nCanopy Growth is another popular marijuana stock that's been an utter disappointment. The company's cash pile has dwindled significantly over the past couple of years, and Canopy is still nowhere close to generating a profit, even after closing two large greenhouses in British Columbia.\nImage source: Starbucks.\nBrand-name companies are popular with millennials\nLastly, you'll note that among the meme stocks, pot stocks, and penny stocks, millennial investors have also piled into brand-name companies that they're familiar with or regularly engage with.\nFor instance, electric-vehicle (EV) manufacturer Tesla has supplanted Apple as the most-held stock in the Robinhood universe. Generally speaking, the desire to take action against climate change increases the younger someone is. Motivated young investors who want to see positive climate action taken, and who have a favorable view of CEO Elon Musk, have flocked to Tesla. In kind, Tesla's production numbers have risen significantly, and could near 800,000 EVs in 2021.\nCoffee giant Starbucks has also been rising up the leaderboard in recent months. It has used its mobile app and rewards as a means to keep the younger generation loyal to its brand. It has also introduced an array of healthier lunches and snack options to improve foot traffic. It definitely doesn't hurt that Starbucks is one of the most-recognized brands in the world.\nBrand-name companies that can engage with young investors are always a good bet to work their way onto Robinhood's leaderboard.","news_type":1},"isVote":1,"tweetType":1,"viewCount":583,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":142064787,"gmtCreate":1626104877449,"gmtModify":1703753579716,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/142064787","repostId":"1143990601","repostType":4,"repost":{"id":"1143990601","pubTimestamp":1626102184,"share":"https://www.laohu8.com/m/news/1143990601?lang=&edition=full","pubTime":"2021-07-12 23:03","market":"fut","language":"en","title":"Oil Slips on Growing Threat of Delta Variant to Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=1143990601","media":"Bloomberg","summary":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurg","content":"<p>(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.</p>\n<p>Futures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.</p>\n<p>“As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.</p>\n<p>Fuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.</p>\n<p>China’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.</p>\n<p>“There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.</p>\n<p>The delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.</p>\n<p>Uncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.</p>\n<p>“They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.</p>\n<p>The International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil Slips on Growing Threat of Delta Variant to Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil Slips on Growing Threat of Delta Variant to Demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-12 23:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.\nFutures in New York fell as much as ...</p>\n\n<a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143990601","content_text":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.\nFutures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.\n“As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.\nFuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.\nChina’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.\n“There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.\nThe delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.\nUncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.\n“They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.\nThe International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":311,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114481303,"gmtCreate":1623087740802,"gmtModify":1704195859336,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/114481303","repostId":"1133110564","repostType":4,"repost":{"id":"1133110564","pubTimestamp":1623080895,"share":"https://www.laohu8.com/m/news/1133110564?lang=&edition=full","pubTime":"2021-06-07 23:48","market":"us","language":"en","title":"Controversial Biogen Alzheimer Drug Wins FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1133110564","media":"zerohedge","summary":"In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's ","content":"<p>In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's experimental drug for treating the physiological causes of Alzheimer's, as the first treatment to address an underlying cause of the disease despite the remaining controversy over the drug's decidedly mixed clinical trial results.</p>\n<p>AsReutersexplains, Aduhelm is one of a long list of drugs that have aimed to remove sticky deposits of a protein called amyloid beta from the brains of patients suffering from early-stage Alzheimer's in order to stave off the worst ravages of the disease, which is characterized by severe memory loss and the loss of the ability to care for oneself.</p>\n<p>The clinical trials for Aduhelm were the first to show that a reduction in these plaques (which are considered a hallmark symptom of the disease) can slow the clinical decline of a patient.</p>\n<p>The drug has created a rift in the professional community that was mentioned inthe FDA's press release: the agency said that the data included in the Biogen's submission - which were derived from two phase 3 clinical trials - were \"highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\" Many scientists opposed the drug's approval, saying it doesn't work.</p>\n<p>As a result, Biogen will be required to conduct another round of post-approval clinical studies (what the FDA is calling a \"Phase 4\" trial).</p>\n<p>Biogen's new drug is the first Alzheimer's treatment approved since 2003. Existing treatment courses for the disease don't do much to arrest the underlying causes, but rather are designed to make patients more comfortable.</p>\n<p>FDA approved Aduhelm to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, which allowed for the drug's approval thanks to the success it showed in reducing the amyloid beta brain plaque.</p>\n<p>Shares of Biogen climbed on the news, as did shares in other companies known to be working on alzheimer treatments, including Biogen rival Eli Lilly. The Nasdaq biotech index climbed to a session high.</p>\n<p><img src=\"https://static.tigerbbs.com/ac26030030981a2daa2396729b972e22\" tg-width=\"500\" tg-height=\"337\"><u><b>Read the full press release below:</b></u></p>\n<p><i>Today FDA approved&nbsp;Aduhelm (aducanumab)&nbsp;to treat patients with Alzheimer’s disease using the&nbsp;Accelerated Approval&nbsp;pathway, under which the FDA approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit.</i></p>\n<p><i>This approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer’s disease since 2003. Perhaps more significantly, Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer’s disease, the presence of amyloid beta plaques in the brain.&nbsp; The clinical trials for Aduhelm were the first to show that a reduction in these plaques—a hallmark finding in the brain of patients with Alzheimer’s—is expected to lead to a reduction in the clinical decline of this devastating form of dementia.</i></p>\n<p><i>We are well-aware of the attention surrounding this approval. We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review. Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.</i></p>\n<p><i>At the end of the day, we followed our usual course of action when making regulatory decisions in situations where the data are not straightforward. We examined the clinical trial findings with a fine-tooth comb, we solicited input from the&nbsp;Peripheral and Central Nervous System Drugs Advisory Committee, we listened to the perspectives of the patient community, and we reviewed all relevant data. We ultimately decided to use the Accelerated Approval pathway—a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit. In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy.</i></p>\n<p><i><b>What the Data Show</b></i></p>\n<p><i>The late-stage development program for Aduhelm consisted of two phase 3 clinical trials. One study met the primary endpoint, showing reduction in clinical decline. The second trial did not meet the primary endpoint. &nbsp;In all studies in which it was evaluated, however, Aduhelm consistently and very convincingly reduced the level of amyloid plaques in the brain in a dose- and time-dependent fashion. &nbsp;It is expected that the reduction in amyloid plaque will result in a reduction in clinical decline.</i></p>\n<p><i>We know that the Peripheral and Central Nervous System Drugs Advisory Committee, which convened in November 2020 to review the clinical trial data and discuss the evidence supporting the Aduhelm application, did not agree that it was reasonable to consider the clinical benefit of the one successful trial as the primary evidence supporting approval. The option of Accelerated Approval was not discussed by the Advisory Committee. As mentioned above, treatment with Aduhelm was clearly shown in all trials to substantially reduce amyloid beta plaques. This reduction in plaques is reasonably likely to result in clinical benefit. After the Advisory Committee provided its feedback, our review and deliberations continued, and we decided that the evidence presented in the Aduhelm application met the standard for Accelerated Approval. We thank the Advisory Committee for its independent review of the data and valuable advice.</i></p>\n<p><i><b>Accelerated Approval</b></i></p>\n<p><i>The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need.&nbsp; Approval is based on a surrogate or intermediate clinical endpoint (in this case reduction of amyloid plaque in the brain).&nbsp; A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.</i></p>\n<p><i>Drug companies are required to conduct post-approval studies to verify the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial does not verify the drug’s anticipated clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.</i></p>\n<p><i><b>The Devastation of Alzheimer’s Disease</b></i></p>\n<p><i>With all this said, we are extremely aware of the gradual and cumulative devastation that Alzheimer’s disease causes, as patients lose their memory and cognitive functioning over time. In late-stage disease, people can no longer hold a conversation or respond to their environment. On average, a person with Alzheimer’s disease lives four to eight years after diagnosis, but some patients can live up to 20 years with the disease.</i></p>\n<p><i>The need for treatments is urgent: right now, more than 6 million Americans are living with Alzheimer’s disease and this number is expected to grow as the population ages. Alzheimer's is the sixth leading cause of death in the United States.</i></p>\n<p><i>Although the Aduhelm data are complicated with respect to its clinical benefits, FDA has determined that there is substantial evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients. &nbsp;As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease.</i></p>\n<p><i>FDA will continue to monitor Aduhelm as it reaches the market and ultimately the patient’s bedside. Additionally, FDA is requiring Biogen to conduct a post-approval clinical trial to verify the drug’s clinical benefit. If the drug does not work as intended, we can take steps to remove it from the market. But hopefully, we will see further evidence of benefit in the clinical trial and as greater numbers of people receive Aduhelm. As an agency, we will also continue to work to foster drug development for this catastrophic disease.</i></p>","source":"lsy1583725640930","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Controversial Biogen Alzheimer Drug Wins FDA Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nControversial Biogen Alzheimer Drug Wins FDA Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 23:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/breakthrough-biogen-alzheimer-drug-wins-fda-approval?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's experimental drug for treating the physiological causes of Alzheimer's, as the first treatment to ...</p>\n\n<a href=\"https://www.zerohedge.com/markets/breakthrough-biogen-alzheimer-drug-wins-fda-approval?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.zerohedge.com/markets/breakthrough-biogen-alzheimer-drug-wins-fda-approval?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133110564","content_text":"In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's experimental drug for treating the physiological causes of Alzheimer's, as the first treatment to address an underlying cause of the disease despite the remaining controversy over the drug's decidedly mixed clinical trial results.\nAsReutersexplains, Aduhelm is one of a long list of drugs that have aimed to remove sticky deposits of a protein called amyloid beta from the brains of patients suffering from early-stage Alzheimer's in order to stave off the worst ravages of the disease, which is characterized by severe memory loss and the loss of the ability to care for oneself.\nThe clinical trials for Aduhelm were the first to show that a reduction in these plaques (which are considered a hallmark symptom of the disease) can slow the clinical decline of a patient.\nThe drug has created a rift in the professional community that was mentioned inthe FDA's press release: the agency said that the data included in the Biogen's submission - which were derived from two phase 3 clinical trials - were \"highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\" Many scientists opposed the drug's approval, saying it doesn't work.\nAs a result, Biogen will be required to conduct another round of post-approval clinical studies (what the FDA is calling a \"Phase 4\" trial).\nBiogen's new drug is the first Alzheimer's treatment approved since 2003. Existing treatment courses for the disease don't do much to arrest the underlying causes, but rather are designed to make patients more comfortable.\nFDA approved Aduhelm to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, which allowed for the drug's approval thanks to the success it showed in reducing the amyloid beta brain plaque.\nShares of Biogen climbed on the news, as did shares in other companies known to be working on alzheimer treatments, including Biogen rival Eli Lilly. The Nasdaq biotech index climbed to a session high.\nRead the full press release below:\nToday FDA approved Aduhelm (aducanumab) to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, under which the FDA approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit.\nThis approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer’s disease since 2003. Perhaps more significantly, Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer’s disease, the presence of amyloid beta plaques in the brain.  The clinical trials for Aduhelm were the first to show that a reduction in these plaques—a hallmark finding in the brain of patients with Alzheimer’s—is expected to lead to a reduction in the clinical decline of this devastating form of dementia.\nWe are well-aware of the attention surrounding this approval. We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review. Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\nAt the end of the day, we followed our usual course of action when making regulatory decisions in situations where the data are not straightforward. We examined the clinical trial findings with a fine-tooth comb, we solicited input from the Peripheral and Central Nervous System Drugs Advisory Committee, we listened to the perspectives of the patient community, and we reviewed all relevant data. We ultimately decided to use the Accelerated Approval pathway—a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit. In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy.\nWhat the Data Show\nThe late-stage development program for Aduhelm consisted of two phase 3 clinical trials. One study met the primary endpoint, showing reduction in clinical decline. The second trial did not meet the primary endpoint.  In all studies in which it was evaluated, however, Aduhelm consistently and very convincingly reduced the level of amyloid plaques in the brain in a dose- and time-dependent fashion.  It is expected that the reduction in amyloid plaque will result in a reduction in clinical decline.\nWe know that the Peripheral and Central Nervous System Drugs Advisory Committee, which convened in November 2020 to review the clinical trial data and discuss the evidence supporting the Aduhelm application, did not agree that it was reasonable to consider the clinical benefit of the one successful trial as the primary evidence supporting approval. The option of Accelerated Approval was not discussed by the Advisory Committee. As mentioned above, treatment with Aduhelm was clearly shown in all trials to substantially reduce amyloid beta plaques. This reduction in plaques is reasonably likely to result in clinical benefit. After the Advisory Committee provided its feedback, our review and deliberations continued, and we decided that the evidence presented in the Aduhelm application met the standard for Accelerated Approval. We thank the Advisory Committee for its independent review of the data and valuable advice.\nAccelerated Approval\nThe FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need.  Approval is based on a surrogate or intermediate clinical endpoint (in this case reduction of amyloid plaque in the brain).  A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.\nDrug companies are required to conduct post-approval studies to verify the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial does not verify the drug’s anticipated clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.\nThe Devastation of Alzheimer’s Disease\nWith all this said, we are extremely aware of the gradual and cumulative devastation that Alzheimer’s disease causes, as patients lose their memory and cognitive functioning over time. In late-stage disease, people can no longer hold a conversation or respond to their environment. On average, a person with Alzheimer’s disease lives four to eight years after diagnosis, but some patients can live up to 20 years with the disease.\nThe need for treatments is urgent: right now, more than 6 million Americans are living with Alzheimer’s disease and this number is expected to grow as the population ages. Alzheimer's is the sixth leading cause of death in the United States.\nAlthough the Aduhelm data are complicated with respect to its clinical benefits, FDA has determined that there is substantial evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients.  As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease.\nFDA will continue to monitor Aduhelm as it reaches the market and ultimately the patient’s bedside. Additionally, FDA is requiring Biogen to conduct a post-approval clinical trial to verify the drug’s clinical benefit. If the drug does not work as intended, we can take steps to remove it from the market. But hopefully, we will see further evidence of benefit in the clinical trial and as greater numbers of people receive Aduhelm. As an agency, we will also continue to work to foster drug development for this catastrophic disease.","news_type":1},"isVote":1,"tweetType":1,"viewCount":444,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":192373380,"gmtCreate":1621153405640,"gmtModify":1704353442582,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/192373380","repostId":"1163454382","repostType":4,"repost":{"id":"1163454382","pubTimestamp":1621004581,"share":"https://www.laohu8.com/m/news/1163454382?lang=&edition=full","pubTime":"2021-05-14 23:03","market":"us","language":"en","title":"Why AMC Entertainment Stock Jumped Again Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1163454382","media":"Motley Fool","summary":"AMC investors have reason for more optimism on the heels of another capital raise.Yesterday's jump came after the company announcedit raised $428 million. First, the Centers for Disease Control and Prevention  issued a new statement on current health and safety protocols saying that fully vaccinated people can resume activities without wearing a mask or physically distancing, including indoors.This should allow theaters to open back up at full capacity and be a desirable destination for vaccinat","content":"<blockquote>\n <b>AMC investors have reason for more optimism on the heels of another capital raise.</b>\n</blockquote>\n<p><b>What happened</b></p>\n<p>A day after<b>AMC Entertainment Holdings</b>(NYSE:AMC)</p>\n<p><b>So what</b></p>\n<p>Yesterday's jump came after the company announcedit raised $428 million</p>\n<p>First, the Centers for Disease Control and Prevention (CDC) issued a new statement on current health and safety protocols saying that fully vaccinated people can resume activities without wearing a mask or physically distancing, including indoors.</p>\n<p>This should allow theaters to open back up at full capacity and be a desirable destination for vaccinated movie patrons. Also yesterday,<b>Walt Disney</b>(NYSE:DIS)announced its quarterly earnings report, and CEO Bob Chapek noted \"increased production at our studios.\" While that is a positive for theater operators, Disney also reported disappointing subscriber growth in itsstreaming services.</p>\n<p><b>Now what</b></p>\n<p>Lower streaming subscriptions could be a positive sign for the theater business. As vaccinations continue to roll out, and with the CDC now officially giving its approval to gather indoors with crowds and without masks, theater attendance may resume quickly.</p>\n<p>Vaccinations are going to drive people back to activities outside the home. Movie theaters are likely to be a favorite destination after more than a year of mostly watching at home. On the heels of another capital raise, AMC investors may be thinking this company finally has a promising path ahead.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why AMC Entertainment Stock Jumped Again Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy AMC Entertainment Stock Jumped Again Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-14 23:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/14/why-amc-entertainment-stock-jumped-again-friday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AMC investors have reason for more optimism on the heels of another capital raise.\n\nWhat happened\nA day afterAMC Entertainment Holdings(NYSE:AMC)\nSo what\nYesterday's jump came after the company ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/14/why-amc-entertainment-stock-jumped-again-friday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/05/14/why-amc-entertainment-stock-jumped-again-friday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163454382","content_text":"AMC investors have reason for more optimism on the heels of another capital raise.\n\nWhat happened\nA day afterAMC Entertainment Holdings(NYSE:AMC)\nSo what\nYesterday's jump came after the company announcedit raised $428 million\nFirst, the Centers for Disease Control and Prevention (CDC) issued a new statement on current health and safety protocols saying that fully vaccinated people can resume activities without wearing a mask or physically distancing, including indoors.\nThis should allow theaters to open back up at full capacity and be a desirable destination for vaccinated movie patrons. Also yesterday,Walt Disney(NYSE:DIS)announced its quarterly earnings report, and CEO Bob Chapek noted \"increased production at our studios.\" While that is a positive for theater operators, Disney also reported disappointing subscriber growth in itsstreaming services.\nNow what\nLower streaming subscriptions could be a positive sign for the theater business. As vaccinations continue to roll out, and with the CDC now officially giving its approval to gather indoors with crowds and without masks, theater attendance may resume quickly.\nVaccinations are going to drive people back to activities outside the home. Movie theaters are likely to be a favorite destination after more than a year of mostly watching at home. On the heels of another capital raise, AMC investors may be thinking this company finally has a promising path ahead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":214,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":142067113,"gmtCreate":1626104891732,"gmtModify":1703753580042,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/142067113","repostId":"1143990601","repostType":4,"repost":{"id":"1143990601","pubTimestamp":1626102184,"share":"https://www.laohu8.com/m/news/1143990601?lang=&edition=full","pubTime":"2021-07-12 23:03","market":"fut","language":"en","title":"Oil Slips on Growing Threat of Delta Variant to Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=1143990601","media":"Bloomberg","summary":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurg","content":"<p>(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.</p>\n<p>Futures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.</p>\n<p>“As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.</p>\n<p>Fuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.</p>\n<p>China’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.</p>\n<p>“There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.</p>\n<p>The delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.</p>\n<p>Uncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.</p>\n<p>“They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.</p>\n<p>The International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil Slips on Growing Threat of Delta Variant to Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil Slips on Growing Threat of Delta Variant to Demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-12 23:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.\nFutures in New York fell as much as ...</p>\n\n<a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143990601","content_text":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.\nFutures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.\n“As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.\nFuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.\nChina’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.\n“There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.\nThe delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.\nUncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.\n“They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.\nThe International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":221,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119455704,"gmtCreate":1622560602508,"gmtModify":1704186405138,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Weeee","listText":"Weeee","text":"Weeee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/119455704","repostId":"2138889344","repostType":4,"isVote":1,"tweetType":1,"viewCount":417,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":111320436,"gmtCreate":1622653635125,"gmtModify":1704188281962,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/111320436","repostId":"2140448417","repostType":4,"isVote":1,"tweetType":1,"viewCount":262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":136463833,"gmtCreate":1622036288122,"gmtModify":1704178243284,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/136463833","repostId":"2138105101","repostType":4,"isVote":1,"tweetType":1,"viewCount":127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":191070754,"gmtCreate":1620830434978,"gmtModify":1704349072893,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SBUX\">$Starbucks(SBUX)$</a>dhisndf","listText":"<a href=\"https://laohu8.com/S/SBUX\">$Starbucks(SBUX)$</a>dhisndf","text":"$Starbucks(SBUX)$dhisndf","images":[{"img":"https://static.tigerbbs.com/727543736fc358cc12dc1929f8d98814","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/191070754","isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":111963117,"gmtCreate":1622649396339,"gmtModify":1704188139993,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".&nbsp;","listText":".&nbsp;","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/111963117","repostId":"1188552613","repostType":4,"isVote":1,"tweetType":1,"viewCount":407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":135084783,"gmtCreate":1622122701142,"gmtModify":1704179864159,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".guu ya n","listText":".guu ya n","text":".guu ya n","images":[{"img":"https://static.tigerbbs.com/f718b1732852edbe5f41671c8998e94e","width":"1125","height":"3282"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/135084783","isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":135086323,"gmtCreate":1622122619562,"gmtModify":1704179859786,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/135086323","repostId":"2138912120","repostType":4,"repost":{"id":"2138912120","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622121480,"share":"https://www.laohu8.com/m/news/2138912120?lang=&edition=full","pubTime":"2021-05-27 21:18","market":"us","language":"en","title":"GM restarting some plants hit by chips shortage","url":"https://stock-news.laohu8.com/highlight/detail?id=2138912120","media":"Reuters","summary":"May 27 (Reuters) - General Motors Co    said Thursday it will be soon be restarting production at fi","content":"<p>May 27 (Reuters) - General Motors Co    said Thursday it will be soon be restarting production at five assembly plants around the world that have been idled due to a global semiconductor chips shortage.</p><p>GM said it is restarting operations at four plants in the United States, Mexico and Canada starting next week. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> plants in Mexico will resume production next week that build the Chevrolet Equinox, GMC Terrain and Chevrolet Blazer.</p><p>Next week GM will also resume full production at its Bupyeong 1 Assembly in Korea, which had been operating at 50% capacity since April 26 and return another Korean assembly plant to two shifts.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GM restarting some plants hit by chips shortage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGM restarting some plants hit by chips shortage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-27 21:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>May 27 (Reuters) - General Motors Co    said Thursday it will be soon be restarting production at five assembly plants around the world that have been idled due to a global semiconductor chips shortage.</p><p>GM said it is restarting operations at four plants in the United States, Mexico and Canada starting next week. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> plants in Mexico will resume production next week that build the Chevrolet Equinox, GMC Terrain and Chevrolet Blazer.</p><p>Next week GM will also resume full production at its Bupyeong 1 Assembly in Korea, which had been operating at 50% capacity since April 26 and return another Korean assembly plant to two shifts.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GM":"通用汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138912120","content_text":"May 27 (Reuters) - General Motors Co    said Thursday it will be soon be restarting production at five assembly plants around the world that have been idled due to a global semiconductor chips shortage.GM said it is restarting operations at four plants in the United States, Mexico and Canada starting next week. Two plants in Mexico will resume production next week that build the Chevrolet Equinox, GMC Terrain and Chevrolet Blazer.Next week GM will also resume full production at its Bupyeong 1 Assembly in Korea, which had been operating at 50% capacity since April 26 and return another Korean assembly plant to two shifts.","news_type":1},"isVote":1,"tweetType":1,"viewCount":211,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":194835491,"gmtCreate":1621352496813,"gmtModify":1704356334000,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/194835491","repostId":"2136995492","repostType":4,"isVote":1,"tweetType":1,"viewCount":383,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":191054560,"gmtCreate":1620829586050,"gmtModify":1704349056534,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Uppppzz&nbsp;","listText":"Uppppzz&nbsp;","text":"Uppppzz","images":[{"img":"https://static.tigerbbs.com/49fdd8247005beda8b462ba7c63653b9","width":"1125","height":"2874"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/191054560","isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}